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THE ROLE OF DUAL SPECIFICITY PHOSPHATASE -11 IN INNATE 
AND ADAPTIVE IMMUNE RESPONSES 
 
Kalyan Chakravarthy Nallaparaju, M.S. 
 
Supervisory Professor: Chen Dong, Ph.D. 
 
Dual-specificity phosphatases (DUSPs) constitute a subfamily of protein 
tyrosine phosphatases characterized by their ability to dephosphorylate both 
phosphotyrosine and phosphoserine/phosphothreonine residues within a substrate, 
typically among members of the MAP kinase family.  DUSPs have been shown to 
play a critical role in the regulation of various cellular processes including signal 
transduction, cell cycle regulation and cellular proliferation via modulation of MAP 
kinase activities. Also, many members of this family have been demonstrated to be 
potent immune regulators. Deregulated expression patterns of DUSPs have been 
associated with pathogenesis in a wide range of diseases. DUSPs are broadly 
classified into six subgroups, of which the atypical subgroup of DUSPs is the least 
studied for their physiological functions.  
 
DUSP11 is an atypical dual specificity phosphatase. Several recent in vitro 
studies highlighted the importance of this molecule in cell proliferation, cancer 
suppression and chronic inflammation. However, the physiological function of 
DUSP11 has not been studied via genetic approaches in vivo. Further, the role of 
 vii 
DUSP11 in regulation of immune responses is not well understood. Our in vitro 
studies show that DUSP11 expression is induced after activation of innate and 
adaptive immune cells, suggesting that DUSP11 may play a role in the regulation of 
immune responses.  To examine the function of DUSP11 in immune cells, we 
generated and analyzed Dusp11-/- mice. We hypothesized that DUSP11 is an 
essential regulator of innate and adaptive immune responses.  
 
Interestingly, we found that Dusp11-/- mice were more susceptible to Listeria 
monocytogenes infection due to defective antigen-specific T cell responses when 
compared with wild-type mice. Further, Dusp11-/- mice were resistant to endotoxin-
induced septic shock and Dusp11-/- dendritic cells had significantly decreased levels 
of pro-inflammatory cytokine production in response to TLR activation, associated 
with reduced NF-κB activation in vitro. Our mechanistic studies demonstrate that 
DUSP11 directly dephosphorylates the gamma binding domain (γbd) of IKK-β and 
thus positively regulates the activity of the IKK complex.  Together, we demonstrate 
for the first time that DUSP11 is a critical regulator of immune responses and acts 
specifically by mediating IKK activation during innate immune responses. This 
phosphatase thus could serve as a novel target for therapeutic intervention for 
inflammatory and autoimmune diseases.   
 
 
 
 
 viii 
TABLE OF CONTENTS 
 
APPROVALS ......................................................................................................... i 
TITLE PAGE ......................................................................................................... ii 
DEDICATION ....................................................................................................... iii 
ACKNOWLEDGEMENTS .................................................................................... iv           
ABSTRACT .......................................................................................................... vi  
TABLE OF CONTENTS  ..................................................................................... viii 
LIST OF FIGURES .............................................................................................. xi 
LIST OF TABLES ................................................................................................ xiii 
ABBREVATIONS ................................................................................................xiv 
CHAPTER 1: INTRODUCTION ............................................................................ 1 
1.1. Protein tyrosine kinases and protein tyrosine phosphatases are critical    
regulators of cell signaling ................................................................................ 3 
1.2. Dual specificity phosphatases ................................................................... 4 
1.3. MAP Kinase signaling and their regulation by MKPs ................................. 8 
1.4. Atypical DUSPs have diverse substrates ................................................. 10 
1.5. DUSPs as regulators of innate and adaptive immune responses ............ 13 
1.6. DUSPs in inflammatory, metabolic disorders and Cancer ....................... 16 
1.7. Dual-specificity phosphatase 11 .............................................................. 17 
1.8. Objective, hypothesis and specific aims of the present work ................... 21 
CHAPTER 2: REGULATION OF IMMUNE RESPONSES BY DUSP11 ............. 24 
BACKGROUND ................................................................................................ 24 
 ix 
RESULTS ......................................................................................................... 27 
2.1. DUSP11 expression is enhanced in dendritic cells upon TLR activation 
and in T cells upon TCR activation ................................................................. 27 
2.2. Generation of Dusp11-/- mice .................................................................. 30 
2.3. Dusp11-/- mice are defective in immune responses against Listeria 
monocytogenes infection ................................................................................ 33 
2.4. Dusp11-/- mice have defective antigen specific immune responses in vivo
 ....................................................................................................................... 38 
2.5. Dusp11-/- mice have defective innate immune responses in vivo and in 
vitro ................................................................................................................. 40 
2.6. DUSP11 is required for CD4 T cell activation and proliferation but 
dispensable for CD4 T cells differentiation in vitro .......................................... 44 
2.7 DUSP11 expression in dendritic cells is required to regulate the T helper 
cell responses in vitro and in vivo ............................................................... …46                    
DISCUSSION ................................................................................................... 51 
CHAPTER 3: MOLECULAR MECHANISMS REGULTED BY DUSP11 IN 
DENDRITIC CELLS ............................................................................................ 54 
BACKGROUND ................................................................................................ 54 
RESULTS ......................................................................................................... 56 
3.1. DUSP11 regulates MAP Kinase signaling in dendritic cells ..................... 56 
3.2. DUSP11 regulates NF-κB signaling in dendritic cells .............................. 61 
3.3. DUSP11 dephosphorylates the gamma binding domain (γbd) of IKK-β ... 68 
DISCUSSION ................................................................................................... 75 
 x 
CHAPTER 4: GENERAL DISCUSSION AND FUTURE DIRECTIONS .............. 79 
4.1. Role of DUSP11 in NF-κB signaling mediated proinflammatory cytokines 
secretion ......................................................................................................... 81 
4.2. Role of DUSP11 in IKK complex activity .................................................. 82 
4.3. Role of DUSP11 in adaptive immune responses ..................................... 85 
4.4. DUSP11’s role as RNA phosphatase ...................................................... 86 
4.5. DUSP inhibitors in preclinical metabolic, autoimmune diseases and cancer 
therapy trials ................................................................................................... 87 
4.6. Significance of the study and future directions ........................................ 90 
CHAPTER 5: EXPERIMENTAL PROCEDURES ................................................ 93 
REFERENCES ................................................................................................  104 
VITA .................................................................................................................. 120 
  
 xi 
LIST OF FIGURES 
 
 
Figure 1. Classification of DUSPs ......................................................................... 7 
Figure 2. Substrate specificities of typical and atypical DUSPs. ......................... 12 
Figure 3. Schematic comparison of DUSP11 with other DUSPs that are shown to 
have immunoregulatory function ......................................................................... 20 
Figure 4. DUSP11 expression is induced in DCs in response to TLR activation 
and in T cells upon TCR activation ..................................................................... 29 
Figure 5. Dusp11 -/- (gene trap) mouse generation ............................................ 31 
Figure 6. Development of T, B, and dendritic cells is normal in Dusp11-/- mice . 32  
Figure 7. Dusp11-/- mice have defective proinflammatory cytokines secretion and 
defective bacterial clearance upon Listeria monocytogenes infection ................. 35  
Figure 8. Dusp11-/- mice have defective innate and adaptive immune responses 
against Listeria monocytogenes infection in vivo ................................................ 36 
Figure 9. Dusp11-/- mice have defective KLH specific immune responses in vivo
 ............................................................................................................................ 39 
Figure 10. Dusp11-/- mice have defective innate immune and inflammatory 
responses in vivo ................................................................................................ 41 
Figure 11. Dusp11-/- mice have defective proinflammatory cytokines secretion in 
vitro in dendritic cells upon stimulation with LPS ................................................ 42 
Figure 12. Dusp11-/- mice have defective proinflammatory cytokines secretion in 
vitro in macrophages upon stimulation with LPS ................................................ 43 
Figure 13. DUSP11 is required for CD4 T cell activation and proliferation but 
dispensable for CD4 T cell differentiation ........................................................... 45 
 xii 
Figure 14. DUSP11 expression in dendritic cells modulates Th1 and Th17 
responses in vitro ................................................................................................ 48 
Figure 15. DUSP11 expression in dendritic cells modulates Th1 and Th17 
responses in vivo ................................................................................................ 49 
Figure 16.  DUSP11 regulates MAP Kinase signaling ........................................ 58 
Figure 17. ERK inhibitor treatment cannot rescue defective proinflammatory 
cytokines secretion in Dusp11-/- DCs ................................................................. 59 
Figure 18. DUSP11 does not regulate stability of proinflammatory cytokine- 
encoding mRNA .................................................................................................. 60 
Figure 19. DUSP11 regulates NF-κB signaling ................................................... 63 
Figure 20. DUSP11 regulates NF-κB signaling ................................................... 64 
Figure 21. NF-κB target genes are down regulated in the absence of DUSP11 . 66 
Figure 22. ERK inhibitor treatment cannot rescue defective NF-κB signaling in 
Dusp11-/- DCs .................................................................................................... 67 
Figure 23. TAK1 and IKK-α/β activation site phosphorylation is not defective in 
Dusp11-/- dendritic cells. .................................................................................... 70 
Figure 24. DUSP11 dephosphorylates γ-binding domain of IKK-β ........................ 71 
Figure 25. DUSP11 dephosphorylates γBD of IKK-β in vitro. .............................. 73 
Figure 26. IKK-β and IKK-γ interaction is not defective in Dusp11-/- dendritic cells.
 ............................................................................................................................ 74 
Figure 27. Proposed model for DUSP11 mediated regulation of NF-κB signaling
 ............................................................................................................................ 78 
 
 xiii 
LIST OF TABLES 
 
 
Table 1. Role of DUSP molecules in generation of innate and adaptive immune 
responses ........................................................................................................... 23 
Table 2. List of Primers  ...................................................................................... 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
ABBREVIATIONS 
 
APC: Antigen Presenting Cell 
CD: Cluster of Differentiation 
CDC14s: Cell Division Cycle 14 phosphatases 
DC: Dendritic Cell 
DUSP: Dual-specificity phosphatases  
ELISA: Enzyme-Linked Immuno Sorbent Assay 
ERK: Extracellular signal-Regulated protein Kinases 
ICS: Intracellular Cytokine Staining  
IFN: Interferon 
IL-2: Interleukin-2 
IL-6: Interleukin-6 
I.P.: Intraperitoneal 
I.V.: Intravenous 
JNK: c-Jun N-terminal kinase 
MAPK: Mitogen Activated Protein Kinase  
MAP2K: MAP Kinase Kinases 
 xv 
MFI: Mean Fluorescence Intensity 
MHC: Major Histocompatibility Complex 
MKPs: Mitogen activated protein Kinase Phosphatases  
NK: Natural Killer 
PAMP: Pathogen Associated Molecular Patterns 
PRL: Phosphatases of Regenerating Liver 
PRR: Pattern Recognition Receptor 
PTENs: Phosphatase and Tensin homologues deleted on chromosome-10  
PTK: Protein Tyrosine Kinase 
PTP: Protein Tyrosine Phosphatase  
TCR: T-Cell Receptor 
TNF-α:  Tumor Necrosis Factor  
Treg cell: T regulatory cell 
 
 
 
 
 1 
CHAPTER-1 INTRODUCTION 
 
 The immune system consists of specialized cells and molecules that defend 
the host against pathogens (Delves and Roitt, 2000a, b).  Fundamentally, immune 
responses against microbes are classified either as innate or adaptive immune 
responses. Innate immune responses serve as a first line of defense against 
infections. However, they are not specific and are not usually sufficient to combat the 
infection. Adaptive immune responses come into play several days after the 
infection, but they are specific against the type of pathogen and also protect the host 
against reinfection from the same pathogen. Both innate and adaptive immune 
responses involve a wide range of cell types that functions as initiators, regulators 
and effectors (Dong et al., 2002). Innate immune cells include phagocytic cells such 
as macrophages, dendritic cells and neutrophils; granulocytes like basophils, mast 
cells and eosinophils; and lymphocytes like natural killer cells (NK cells) (Delves and 
Roitt, 2000a, b).  Adaptive immune cells include B and T lymphocytes. All of these 
cells communicate and counter regulate one another by cell-cell contact or by 
secreting cytokines to generate optimum immune responses against pathogens 
(Dong et al., 2002). Any disruption in this regulation may result in chronic 
inflammation potentially leading to inflammatory and autoimmune diseases. The 
immune cells are tightly regulated at multiple levels during the activation as well as 
the termination of immune responses. This regulation involves both cell intrinsic 
mechanisms in the activated cells or cell extrinsic mechanisms mediated by other 
cell populations such as regulatory T cells (Tregs) (Peggs et al., 2008).   
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Innate immune cells recognize the evolutionarily conserved structures of 
pathogens known as pathogen associated molecular patterns (PAMPs). These 
PAMPs are recognized by pattern recognizing receptors (PRRs) expressed either on 
the surface or inside the innate immune cells (Lang et al., 2006; Mogensen, 2009). 
Several families of PRRs like Toll like receptors (TLRs), retinoic acid inducible gene I 
(RIG-I)-like receptors (RLRs) and the nucleotide-binding domain and leucine-rich 
repeat-containing receptors (NLRs) have been well characterized in last decade 
(Iwasaki and Medzhitov, 2010). Based on the nature of the infection one or more 
PRRs are activated by PAMPs, several signaling transduction pathways are rapidly 
activated to mediate gene expression and the synthesis of several immune 
molecules like cytokines, chemokines etc. Two major pathways that are involved in 
proinflammatory cytokine expression are the evolutionarily conserved MAP kinase 
signaling cascade and the NF-κB signaling cascade (Dong et al., 2002; Lang et al., 
2006). The magnitude and duration of the innate immune responses are tightly 
regulated by several endogenous molecules like kinases and phosphatases that 
activate and deactivate these signaling pathways (Mogensen, 2009). In the case of 
adaptive immune cells, MAP Kinase and NF-κB signaling pathways are involved 
downstream of activating and inhibitory receptors to ensure optimum T cell and B 
cell response activation (Peggs et al., 2008). Therefore, these signaling pathways 
function as rheostats in both the innate and adaptive immune responses. Although 
their upstream activation signals vary, understanding the regulatory elements 
controlling this activation is essential. Regulation of cell signaling by protein tyrosine 
kinases and phosphatases will be discussed in detail in the next section. 
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1.1. Protein tyrosine kinases and protein tyrosine phosphatases are critical 
regulators of cell signaling 
 
Protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) 
regulate a wide variety of fundamental signaling and physiological pathways by 
reversible phosphorylation of proteins (Alonso et al., 2004; Hunter, 1995; Patterson 
et al., 2009; Tonks and Neel, 1996). Generally, the PTKs activate cell signaling by 
phosphorylating the protein substrates whereas the PTPs deactivate cell signaling 
by dephosphorylating the protein substrates (Patterson et al., 2009). However, in 
some exceptional cases phosphorylation of regulatory domains of proteins leads to 
deactivation of downstream signaling (Higashimoto et al., 2008). Though the role of 
PTKs in cell signaling is well established due to their early identification (Czernilofsky 
et al., 1980; Patterson et al., 2009), recent research is being focused on PTPs which 
has resulted in an increased understanding of the dynamics PTPs and PTKs play in 
fundamental physiological processes. This protein phosphorylation is reversible and 
tightly regulated and any aberrations in this process results in numerous diseases 
including cancer and immune deficiencies (Patterson et al., 2009; Tonks, 2006).  
Therefore, understanding this balance of signaling by PTKs and PTPs is critical for 
the development of new diagnostic and therapeutic strategies for the above 
mentioned diseases. Though PTPs and PTKs comprise of a large number of 
molecules and are classified into several sub families, in the interest of the present 
study the role of a sub family of PTPs, known as dual specificity phosphatases 
(DUSPs) in physiological processes and human disease will be further discussed.  
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1.2.  Dual specificity phosphatases 
 
 Dual-specificity phosphatases (DUSPs) constitute a subfamily of protein 
tyrosine phosphatases that are characterized by their ability to dephosphorylate both 
phosphotyrosine and phosphoserine/ phosphothreonine residues within a substrate 
(Patterson et al., 2009; Pulido and Hooft van Huijsduijnen, 2008; Zhang and Dong, 
2007; Zhang and Dong, 2005). DUSPs have been shown to play critical roles in the 
regulation of various cellular processes such as signal transduction (Zhang et al., 
2004), cell cycle regulation (Karlsson-Rosenthal and Millar, 2006) and cellular 
proliferation (Zhang et al., 2009)  via modulation of their substrate activities. 
Deregulated expression patterns of DUSPs have been associated with pathogenesis 
in a wide range of diseases such as colon cancer, multiple sclerosis etc. (Tonks, 
2006).   All the members of this subfamily have a highly conserved catalytic domain 
also known as the phosphatase domain which consists of a consensus sequence 
HCXXXXXR with conserved aspartic acid, cysteine and arginine residues forming 
the catalytic site (Huang and Tan, 2012). DUSPs share a common mechanism of 
catalysis in dephosphorylating their substrates by forming a stable phosphoryl-
intermediate (Denu and Dixon, 1995; Niwa et al., 2002).     
 
Currently, there are 61 members identified as DUSPs. Based on their domain 
homology and sequence similarity, these DUSPs are broadly classified into seven 
subgroups (Fig 1). They include slingshot phosphatases, phosphatases of 
regenerating liver (PRL), cell division cycle 14 phosphatases (CDC14), phosphatase 
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and tensin homologues deleted on chromosome-10 (PTEN), myotubularins, mitogen 
activated protein kinase phosphatases (MKP) and atypical DUSPs (Patterson et al., 
2009).  Among these, CDC14s are well studied for their role in cell cycle regulation 
and tumor suppression (Trautmann and McCollum, 2002)  and PTENs (Wang and 
Jiang, 2008; Wishart and Dixon, 2002) and MKPs for their role in cell signaling 
(Zhang and Dong, 2007). The atypical subgroup of DUSPs is the least studied for 
their physiological functions (Patterson et al., 2009). MKPs (also known as typical 
DUSPs) and atypical DUSPs are both designated as DUSPs (Lang et al., 2006). 
Until recently the low molecular weight atypical DUSPs were grouped with MKPs as 
they also are thought to negatively regulate MAP Kinase activity.  
 
Indeed, a few atypical DUSPs may function as MKPs as several members 
like DUSP14 (Marti et al., 2001), DUSP3 (Todd et al., 1999) and DUSP22 (Alonso et 
al., 2002; Chen et al., 2002) are shown to dephosphorylate MAPK substrates. But 
other members were shown to have other diverse substrates like STAT molecules 
for DUSP3 (Hoyt et al., 2007; Najarro et al., 2001) or Glucokinase for DUSP12 
(Munoz-Alonso et al., 2000). Together, MKP and atypical sub group are comprised 
of 30 members out of which 11 are bona fide MKPs and 19 are atypical 
DUSPs(Alonso et al., 2004).  The atypical DUSPs lack the N-terminal Cdc25 
homology 2 (CH2) domains and a MAP Kinase-binding (MKB) motif or Kinase 
interacting motif (KIM) that is commonly present in MKPs (Huang and Tan, 2012; 
Lang et al., 2006).  Recent studies indicate the potential of these atypical DUSPs as 
crucial signaling regulators (Patterson et al., 2009). Currently, the in vivo 
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physiological functions of most atypical DUSPs are still unknown. Studying the in 
vivo functions of atypical DUSPs by generating KO mouse models would provide a 
better understanding of their importance in various disease models. In the current 
study’s interest, the MKPs and atypical DUSPs will be further described in the next 
section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Classification of DUSPs
sequence similarity, these DUSPs are broadly clas
(Patterson et al., 2009). They include slingshot phosphatases, phosphatases of 
regenerating liver (PRLs), cell division cycle 14 phosphatases (CDC14s), 
phosphatase and tensin homologues deleted on chromosome
myotubularins, mitogen activated protein kinase phosphatases (MKPs) and atypical 
DUSPs.  
 
 
. Based on their domain homology and 
sified into seven subgroups
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-10 (PTENs), 
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1.3. MAP Kinase signaling and their regulation by MKPs 
 
Mitogen activated protein kinase (MAPK) signaling pathway is evolutionarily 
conserved, tightly regulated and is essential for many physiological processes (Dong 
et al., 2002). Mammalian species mainly have three families of MAPKs including 
extracellular signal-regulated protein kinases (ERKs), c-Jun NH2-terminal kinases 
(JNKs) and p38 MAPK. All these MAPK members have a Thr-X-Tyr motif in their 
activation loop and their phosphorylation by upstream MAP kinase kinases 
(MAP2Ks) is essential for their activation (Zhang and Dong, 2005).  MAP kinases 
are activated by various extracellular and intracellular factors and they transduce the 
signals to alter gene regulation and ultimately cellular function.  The magnitude and 
duration of MAPKs activation are critical for having optimum physiological effect. 
Therefore, tight regulation of these pathways is essential.  The activities of these 
MAP Kinases are negatively regulated by MKPs (Zhang and Dong, 2007).  As 
mentioned before, all the members of MKP subgroup and few members of atypical 
DUSP subgroups have MAPKs as their substrates.  These members have substrate 
specificities for one or more MAPKs (Fig 2A). Unlike their substrate MAPKs which 
are ubiquitously expressed, the expression of MKP members varies between cell 
types and cellular localization (Zhang and Dong, 2005). Most of these members are 
early response genes i.e. their expression remains low in resting cells but increases 
rapidly upon appropriate stimulation, including  cytokines or TLR ligand stimulations 
(Patterson et al., 2009).  The degree of expression between the members varies 
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considerably for a given stimuli and is often dependent on their substrate MAPK 
activation (Ekerot et al., 2008; Keyse, 2000).  
 
The substrate specificities of these DUSPs vary considerably between in vitro 
and in vivo studies (Zhang and Dong, 2005). For example, DUSP1/MKP-1 
(Theodosiou et al., 1999) and DUSP6/MKP-5 (Tanoue et al., 1999)  were previously 
demonstrated to dephosphorylate p38 and JNK in in vitro studies. However, using 
specific knock-out mouse models, our group and others have demonstrated that 
DUSP6 is JNK specific phosphatase in vivo (Zhang et al., 2004). Another example is 
DUSP2 where in vitro studies showed ERK & p38 are the substrates (Ward et al., 
1994), but in vivo JNK is demonstrated to be the substrate (Jeffrey et al., 2006). This 
difference between in vitro and in vivo studies could be because of artificial settings 
in vitro or due to the compensatory mechanisms of other MKP family members or 
due to the involvement of scaffold proteins in vivo to facilitate the dephosphorylation 
of MAPKs. Therefore, it is essential to study the knock-out models of all the DUSP 
family members to identify the right substrate in vivo for these molecules (Zhang and 
Dong, 2005).  
 
Several of these family members are also involved in development and this 
feature of MKPs is evolutionally conserved. In Drosophilla, puckered (puc gene) a 
JNK phosphatase is essential for embryogenesis (Martin-Blanco et al., 1998) and for 
Caenohabditis elegans, VHP-1 which is a JNK phosphatase is required for larval 
development (Mizuno et al., 2004). In mammals, DUSP9 is shown to be essential for 
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placental development (Christie et al., 2005). Further, our recent studies 
demonstrated that DUSP16/MKP7 is essential for embryonic development and 
absence or mutation of this gene results in arrest of embryonic development around 
E.13 to E.15 (Nallaparaju & Zhang et.al, unpublished data). Together, these studies 
highlight the essentiality of DUSPs in cell signaling regulation and development. 
 
1.4. Atypical DUSPs have diverse substrates  
 
Although several members of atypical DUSPs like DUSP3 (Todd et al., 1999) 
and DUSP14 (Marti et al., 2001) functions as MKPs these are phylogenetically 
distinct from the typical DUSPs and PTPs (Patterson et al., 2009). These members 
are closely related to VH1 (Vaccinia virus open reading from H1) phosphatase of 
Vaccinia virus (Liu et al., 1995). They are low in molecular weight and have wide 
range of substrate specificities (Fig 2B). For example, Glucokinase is demonstrated 
to interact with DUSP12 and is shown to be its substrate (Munoz-Alonso et al., 
2000). In case DUSP22, STAT3 is demonstrated to be the substrate (Sekine et al., 
2007; Sekine et al., 2006) in addition to JNK (Chen et al., 2002; Shen et al., 2001).  
Recent in vitro studies identified DUSP14 as a negative regulator of TNF and IL-1 
induced NF-κB signaling by dephosphorylating TAK1 (Zheng et al., 2013). In case of 
DUSP22, a recent study identified focal adhesion kinase (FAK) as its interacting 
partner and is shown to involve in regulation of cell migration in lung cancer cells (Li 
et al., 2010).  Together, these studies highlight the involvement of non MAPK 
proteins as substrates of atypical DUSPs (Huang and Tan, 2012). However, most of 
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the literature about atypical DUSPs is from in vitro studies and these findings are 
often controversial as in the case of DUSP3. One in vitro study using enzyme 
kinetics and cell transfections identified ERK1/2 as specific substrate (Todd et al., 
1999) but other studies demonstrated that JNK could be the substrate but not the 
ERK (Zhou et al., 2002) (Todd et al., 2002).  Therefore, it is essential to confirm 
these observations in vivo using knockout mouse models to understand the atypical 
DUSPs’ roles in physiological processes and disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Substrate specificities of typical and atypical DUSPs.
DUSPs mainly have one of the three MAP kinases as substrates as in case of 
DUSP2, DUSP4 and DUSP10
DUSP1. (B) In addition to MAP Kinases
substrates like STATs in case of DUSP3, AKT in case of DUSP12
substrates like RNA in case of DUSP11.
 or two MAP Kinases JNK and p38α
, atypical DUSPs have diverse range of 
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 (A)  Typical 
 as in case of 
 or non-protein 
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1.5. DUSPs as regulators of innate and adaptive immune responses 
 
Many members of typical and atypical DUSP families have been 
demonstrated to be potent immune regulators (Huang and Tan, 2012; Lang et al., 
2006; Liu et al., 2007; Patterson et al., 2009). Our group and several other groups 
have highlighted the essentiality of DUSP family members in the regulation of both 
innate and adaptive immune responses (Huang et al., 2011; Zhang et al., 2004; 
Zhang et al., 2009). The first in vivo study showing the involvement of a DUSP family 
member in immune responses came from our group; using Dusp10 knockout mice, 
Zhang et al. demonstrated that DUSP10 functions as a negative regulator of 
proinflammatory cytokine production by innate immune cells. Using in vitro TLR 
ligand stimulations and in vivo septic shock and Listeria monocytogenes infection 
experiments, this study demonstrated that Dusp10-deficient animals have enhanced 
proinflammatory cytokines like TNF-α and IL-6 compared to their WT counterparts. 
Further, this same study demonstrated that that DUSP10 acts intrinsically as positive 
regulator of T cell activation and proliferation but functions as a negative regulator of 
T cell effector function (Zhang et al., 2004). DUSP1 is one other such molecule 
whose function in innate and adaptive immune responses are well studied by 
several groups. Dusp1-/- macrophages and dendritic cells have enhanced 
proinflammatory cytokine TNF-α and IL-6 levels upon stimulation with various TLR 
ligands in vitro (Salojin et al., 2006; Zhao et al., 2005; Zhao et al., 2006). In the case 
of adaptive immune responses, our group has demonstrated that DUSP1 intrinsically 
is essential for T cell activation and proliferation by regulating JNK activity and 
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NFATc1 nuclear translocation. Further, this study demonstrated that Dusp1-/- mice 
have defective immune responses against influenza virus and are resistant to 
experimental autoimmune encephalomyelitis (EAE), a well-established mouse model 
for multiple sclerosis (Zhang et al., 2009). Another study from Chi and colleagues 
demonstrated that DUSP1 mediated signaling in dendritic cells is critical for the fate 
of adaptive T-cell immune responses to either become Th1 cells or Th17 cells. 
DUSP1 does this by regulating the polarizing cytokines and the respective cytokine 
receptors expression at the DC-T cell interface (Huang et al., 2011). One other 
DUSP family member DUSP2 is also well studied for its role in immune responses. 
Dusp2-/- mice were defective in proinflammatory cytokine production in 
macrophages in vitro and in vivo in rheumatoid arthritis model. This study highlighted 
the role of DUSP2 as positive regulator of in macrophages and mast cells (Jeffrey et 
al., 2006).  
 
In a recent study from our lab, we showed that the expression of DUSP16, 
also known as MKP7, was induced in T cells upon TCR activation. To elucidate the 
physiological function of MKP7, we disrupted the Mkp7 gene in mice and found that 
MKP7 is required for embryonic development. As Mkp7 KO is embryonic lethal, to 
understand the function of MKP7 in immunity, we generated Mkp7+/+ and Mkp7-/- 
fetal liver chimeras. Mkp7-/- CD4+ T cells exhibited enhanced ERK and JNK 
activation and produced increased amounts of IL-2 compared with Mkp7+/+ cells 
upon activation. Mkp7-/- CD4+ T cells, though their Th1 and Th2 differentiation was 
not affected, were defective in Th17 differentiation in vitro, which was rescued by 
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blocking IL-2 or inhibition of ERK activation. Furthermore, mice carrying Mkp7-/- T 
cells were deficient in their generation of Th17 and T follicular helper cells in vivo 
and were resistant to autoimmune experimental encephalomyelitis. Our results thus 
demonstrated an essential role of MKP7 in effector T cell function (Nallaparaju and 
Zhang et al.; Manuscript under review).  Another recent study addressed the role of 
MKP7 as negative regulator of TLR induced proinflammatory cytokines in innate 
immune macrophages (Niedzielska et al., 2014). The roles of several other typical 
DUSP members like DUSP4 (Huang et al., 2012; Yu et al., 2012) and DUSP5 
(Kovanen et al., 2008) in immune responses were also recently published by several 
other groups.  
 
Several atypical DUSP subgroup members were shown to be potent immune 
regulators as well.  DUSP14 was identified as interacting partner of T-cell co-
stimulatory factor CD28 by yeast two-hybrid system and co-immunoprecipitation 
assays (Marti et al., 2001; Nakano, 2007).  A recent in vivo study using Dusp14-/- 
mice identified this molecule as a negative regulator of T cell receptor (TCR) 
signaling by dephosphorylating TGF-β-activated kinase 1 (TAK1)-binding protein 1 
(TAB1) (Yang et al., 2014).  Another recent in vitro study identified DUSP14 as a 
negative regulator of TNF and IL-1 induced NF-κB signaling by dephosphorylating 
upstream TAK1 (Zheng et al., 2013).  Another atypical DUSP, DUSP22 was recently 
identified as a regulator of TCR signaling by dephosphorylating Src-family tyrosine 
kinase member Lck. Further, this study reported that Dusp22-/- mice have enhanced 
T cell mediated immune responses and are more susceptible to EAE (Li et al., 
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2014).  Together, these studies demonstrate the indispensable role of typical and 
atypical DUSPs as regulators of immune responses.  
 
1.6. DUSPs in inflammatory, metabolic disorders and cancer 
 
Since DUPS members’ role in immune responses is well established, it is 
reasonable to assume that they are critical in controlling various inflammatory 
diseases. Indeed, several mice and human studies have proved this point.  As 
previously mentioned, DUSP10’s involvement in EAE is studied by our group (Zhang 
et al., 2004). The role of DUSP2 in a mouse model of rheumatoid arthritis is 
published and is shown to play a proinflammatory role (Jeffrey et al., 2006).  
Contrastingly, DUSP1 is shown to play anti-inflammatory role in arthritis model 
(Salojin et al., 2006).  Further, several members of this subgroup are shown to play 
regulatory roles in metabolic disorders like diet induced obesity and stress induced 
insulin resistance.  DUSP1 deficient mice were shown to be resistant to diet-induced 
obesity due to an increase in fatty acid metabolism and enhanced energy 
expenditure (Wu et al., 2006).  DUSP4 has a protective role in stress induced insulin 
resistance in mice by dephosphorylating ERK and JNK (Emanuelli et al., 2008).   
 
 In cancer, several DUSP members function as tumor suppressors (Patterson 
et al., 2009). One such member that is well characterized for its tumor suppressor 
role is DUSP6. In pancreatic cancer patients, DUSP6 is commonly under expressed 
in primary tumors and this is resulted by hypermethylation of the experimental 
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control region of DUSP6 (Xu et al., 2005). Further, this loss of expression of DUSP6 
is correlated with tumor progression. DUSP6 is also shown to have a tumor 
suppressive role in ovarian cancers (Chan et al., 2008). However, as their in vivo 
target substrates greatly vary, not all members of DUSP family function as tumor 
suppressors. DUSP1 was shown to play a positive role in tumor progression of 
pancreatic cancer patients (Liao et al., 2003).  However, in the case of other types of 
cancers like ovarian and testicular cancers, DUSP1 has a negative role in tumor 
progression (Murty et al., 1996). So, depending on the type and the stage of cancer, 
the DUSPs may have different roles. In summary DUSP family members provide a 
potential avenue for therapeutic approaches in autoimmune, inflammatory diseases 
and cancer. Further studying the role of uncharacterized members of these 
subgroups of PTPs is essential to design new therapies and diagnostic approaches.  
DUSP11 is one such member whose physiological role is not well established.     
 
1.7. Dual-specificity phosphatase 11 
 
DUSP11 is also known as PIR1 (phosphatase that interacts with RNA–
ribonucleoprotein complex 1) due to its high affinity for RNA substrates in vitro 
(Deshpande et al., 1999; Yuan et al., 1998). Expression of DUSP11 is observed in 
several human cell lines derived from keratinocytes, epidermoid cells and 
myeloblastic cells, but its tissue distribution has not been studied in detail (Yuan et 
al., 1998). Using a yeast two-hybrid system, Yuan et al. demonstrated that DUSP11 
associates with the splicing factors 9G8 and SRp30C. However, they could not 
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confirm this observation in mammalian cells (Yuan et al., 1998). Using affinity-
purified GST (glutathione transferase)-tagged DUSP11 fusion protein, Deshpande et 
al. showed that DUSP11 has intrinsic phosphatase activity against phosphotyrosine 
residues in vitro, but no or weak activity against phosphoserine/ phosphothreonine 
residues (Deshpande et al., 1999). Also, they demonstrated that the activity of 
DUSP11 as an mRNA triphosphatase is several orders of magnitude greater than as 
a protein phosphatase. These studies suggest that DUSP11 may act in association 
with other mRNA phosphatases and facilitate mRNA maturation. Moreover, DUSP11 
contains two arginine-rich and a proline-rich region that are commonly found in some 
RNA binding proteins (Deshpande et al., 1999). Schematic representation of 
DUSP11 in comparison to other well characterized DUSPs that are shown to have 
immunoregulatory function is depicted in Figure 3. Like other atypical DUSP 
members, DUSP11 lacks CH2 domain that is thought to be essential for interaction 
with MAP kinase substrates. Recent in vitro studies by Caprara et al (Caprara et al., 
2009) and Hasler et al (Hasler et al.) highlight the importance of this molecule in cell 
proliferation, cancer suppression and chronic inflammation. Many DUSP genes have 
been demonstrated to be highly deregulated in the initial stages of cancer and have 
been shown to be tumor regulative. Recently, Helin and colleagues in an in vitro 
study using cell lines demonstrated that DUSP11 is up regulated in a p53 dependent 
manner after treatment with DNA damaging agents and suggested that DUSP11 
contributes to p53-dependent inhibition of cell proliferation (Caprara et al., 2009). 
Using ShRNA knockdown experiments this study highlighted the role of DUSP11 as 
a tumor suppressor gene. Further, they demonstrated that DUSP11 interacts with a 
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splicing factor SAM68 (Src-associated protein in mitotic cells).  Further, Dardousis et 
al. identified DUSP11 as one of the up regulated factors in HT-29 colon carcinoma 
cell lines (Dardousis et al., 2007).  Moreover, studies in inflammatory bowels disease 
(IBD) patients demonstrate that expression of DUSP11 is down regulated in the 
mucosal tissue of colon compared to healthy individuals, highlighting its potentially 
suppressing role in chronic inflammation (Hasler et al., 2011).  However, the 
physiological function of DUSP11 has not been studied via genetic approaches in 
vivo.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic comparison of
to have immunoregulatory function. 
be essential for interaction of DUSP with MAPK substrates. Instead, it has proline 
and arginine rich regions that are usually present in mRNA interacting proteins. 
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1.8. Objective, hypothesis and specific aims of the present work 
 
Though several studies evaluated the role DUSP11 in cell cycle regulation, 
tumor suppression and chronic inflammation in vitro, the role of DUSP11 in immune 
responses is unknown. A microarray screening performed by our laboratory to 
identify the potential regulators of innate and adaptive immune responses identified 
DUSP11 as one factor, along with other DUSP family members like DUSP1 (Zhang 
et al., 2009), DUSP10 (Zhang et al., 2004) and DUSP16 (Nallaparaju & Zhang et al., 
under review) that are highly induced in immune cells upon activation. The functions 
of three of these molecules DUSP1 (Zhang et al., 2009), DUSP10 (Zhang et al., 
2004) and DUSP16 (Nallaparaju & Zhang et al., under review) as critical regulators 
of immune responses were confirmed in vivo by our group using gene knockout 
approaches. The phenotypes of these mice in innate and adaptive immune 
responses are summarized in Table 1. Since DUSP11 is identified in the same 
screening along with the other three members, we hypothesized that DUSP11 is a 
potential regulator of immune responses.  Additionally, Arimura et al. identified 
DUSP11 as one of the seven highly expressed PTP family members among several 
immune cell lineages including dendritic cells, macrophages and T cells (Arimura 
and Yagi, 2010).  Further, our in vitro studies showed that DUSP11 expression is 
induced after activation of innate immune cells by several TLR ligands and in 
adaptive immune cells by anti-CD3 and anti-CD28 agonistic antibodies (Fig 4), 
suggesting that DUSP11 may play a role in regulation of immune responses. 
Additional in vivo studies in animal models are required to elucidate the physiological 
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function of DUSP11. The main objective of my dissertation is to understand the role 
of DUSP11 in innate and adaptive immune responses against pathogens by 
employing the DUSP11 KO mice we generated in our laboratory. In particular, our 
aim is to understand the molecular mechanisms and the signaling events regulated 
by DUSP11 in immune cells. To our knowledge, this is the first study to investigate 
the essentiality of DUSP11 in regulating immune responses. Once the role of this 
protein is elucidated, modulating its expression may be a potential avenue for future 
therapy in inflammatory and autoimmune diseases.  
 
Based on our in vitro studies and published literature about DUSP11 we 
hypothesized that DUSP11 regulates innate and adaptive immune responses by 
regulating TLR and TCR signaling pathways respectively. To address our 
hypothesis, in chapter 2 we have determined whether DUSP11 is critical to induce 
optimal immune responses against pathogens. Further, in Chapter 3 we evaluated 
the signaling pathways regulated by DUSP11 to identify substrate of DUSP11 in 
immune cells.  
 
 
 
 
 
 
 
 Table 1. Role of DUSP molecules in generation of 
responses.  The innate and adaptive immune responses phenotype 
mice deficient in each of the DUSP members identified in our microarray screen is 
summarized in the following table.
 
 
innate and adaptive immune 
observed in the 
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CHAPTER 2 – REGULATION OF IMMUNE RESPONSES BY DUSP11 
 
 
BACKGROUND 
 
 DUSPs have been shown to play critical roles in regulation of various cellular 
processes such as signal transduction, cell cycle regulation and cellular proliferation 
via modulating MAP kinase activities (Patterson et al., 2009). Also, many members 
of this family have been demonstrated to be potent immune regulators (Lang et al., 
2006; Zhang and Dong, 2007; Zhang and Dong, 2005). Deregulated expression 
patterns of DUSPs have been associated with pathogenesis of a wide range of 
diseases including inflammatory, autoimmune diseases and several types of cancer 
(Patterson et al., 2009; Pulido and Hooft van Huijsduijnen, 2008).  DUSPs are 
broadly classified into six subgroups, among which the atypical subgroup of DUSPs 
is the least studied for their physiological functions (Patterson et al., 2009). 
 
DUSP11 (also known as PIR1 (Deshpande et al., 1999; Yuan et al., 1998)) is 
an atypical dual specificity phosphatase (Patterson et al., 2009). An in vitro study in 
cell lines by Caprara et al. showed that DUSP11 is up-regulated in a p53 dependent 
manner after treatment with DNA damaging agents and suggested that DUSP11 
contributes to p53-dependent inhibition of cell proliferation (Caprara et al., 2009). 
This study highlighted the potential role of DUSP11 as a tumor suppressor gene. 
Two other in vitro studies by Yuan et al. and Deshpande et al. demonstrated 
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DUSP11s’ ability to phosphotyrosine and phosphoserine/ phosphothreonine 
substrates in vitro (Deshpande et al., 1999; Yuan et al., 1998). Further, they 
demonstrated that the activity of DUSP11 as an mRNA triphosphatase is  several 
orders of magnitude greater than as a protein phosphatase. These studies together 
suggest that DUSP11 may act in association with other mRNA phosphatases and 
facilitate mRNA maturation. Though these studies together suggested the plausible 
physiological role of DUSP11, it is essential to the study the physiological function of 
this phosphatase in vivo using genetic knockout mouse strain specifically lacking this 
protein to better understand its function in physiology and disease so that it can be 
potentially targeted for therapeutic or diagnostic purposes.  
 
The role of DUSP11 in immune responses remains largely unknown. A study 
in inflammatory bowel disease patients demonstrate that expression of DUSP11 is 
down regulated in the mucosal tissue of colon compared to healthy individuals, 
highlighting its potential role in suppressing chronic inflammation (Hasler et al., 
2011).  Additionally, Arimura et al. identified DUSP11 as one of the seven highly 
expressed PTP family members among several immune cell lineages including 
dendritic cells, macrophages and T cells (Arimura and Yagi, 2010). Moreover, a 
microarray screening performed by our laboratory to identify the potential regulators 
of innate and adaptive immune responses identified DUSP11 as one factor, along 
with other DUSP family members like DUSP1 (Zhang et al., 2009), DUSP10 (Zhang 
et al., 2004)  and DUSP16 (Nallaparaju & Zhang et al., under review), whose 
functions as critical immune regulators is confirmed in vivo by gene knockout 
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approaches.  Further, our in vitro studies showed that DUSP11 expression is 
induced after activation of innate immune cells by several TLR ligands and in 
adaptive immune cells by anti-CD3 and anti-CD28 agonistic antibodies, suggesting 
that DUSP11 may play a role in regulation of immune responses. Based on these 
studies, we hypothesized that DUSP11 is a critical regulator of innate and adaptive 
immune responses against pathogens. 
 
To examine the function of DUSP11 in regulating immune responses, we 
generated and analyzed Dusp11-/- mice. Dusp11-deficient mice exhibit increased 
susceptibility to Listeria monocytogenes infection than wild-type animals and are 
protected from endotoxin-induced septic shock. In vitro, DUSP11 KO dendritic cells 
produce decreased levels of pro-inflammatory cytokines in response to TLR 
activation. Together, we demonstrate for the first time that DUSP11 is a critical 
regulator of immune responses and acts specifically by modulating innate immune 
responses. This phosphatase thus could serve as a novel target for therapeutic 
intervention for innate cell-mediated inflammatory and autoimmune diseases.  
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RESULTS 
 
2.1. DUSP11 expression is enhanced in dendritic cells upon TLR activation 
and in T cells upon TCR activation 
 
As a first step to understand the role of atypical DUSP11 in immune 
responses, we analyzed the expression of DUSP11 in cells of the immune system. 
To address the role of DUSP11 in innate immune cells, bone marrow derived 
dendritic cells (BMDCs) were cultured from WT B6 mice in presence of GM-CSF for 
7 days. These BMDCs were then stimulated with different TLR ligands in vitro to 
study the expression DUSP11 using RT-PCR. Our studies showed that DUSP11 
mRNA expression was highly induced after activation of BMDCs by with various TLR 
ligands like peptidoglycan (PGN) that activates TLR2, Poly (I:C) that activates TLR3 
and LPS that activates TLR4 but not by CpG which activates TLR9 (Fig. 4a). 
Further, we studied the kinetics of DUSP11 induction in BMDCs upon stimulation 
with LPS (Fig. 4b) and identified that DUSP11 is induced as early as 30 min after 
stimulation suggesting that it is an early response gene. Together, these data 
suggest a potential regulatory role of DUSP11 in innate immune responses. 
 
To address the possible role of DUSP11 in T cells, we examined the 
expression of DUSP11 in naïve CD4+ T cells after stimulation with anti-CD3 
antibody for various time points and in effector Th cells, including Th1, Th2 and Th17 
cells, using quantitative RT-PCR. DUSP11 mRNA expression was greatly increased 
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at 1h after anti-CD3 stimulation and the expression level was maintained at 1.5 h 
after stimulation (Fig. 4C).  DUSP11 was also expressed in Th1, Th2, Th17 effector 
cells at a comparable level (Fig. 4D). These data suggest a possible regulatory role 
of DUSP11 in naïve CD4+ T cell activation and CD4+ effector cell function.  
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Figure 4. DUSP11 expression is induced in DCs in response to TLR activation 
and in T cells upon TCR activation. (A) BMDCs were stimulated with different TLR 
ligands for 4h and DUSP11 expression was analyzed by quantitative real-time PCR 
(QRT).  (B) BMDCs were stimulated with LPS (10 ng/ml) for different time points and 
DUSP11 induction kinetics were analyzed by QRT. (C) FACS-sorted naïve CD4+ T 
cells were activated with anti-CD3 (1 µg/ml)   antibody for different time points and 
DUSP 11 induction kinetics was analyzed by QRT. (D)  In vitro differentiated Th1, 
Th2 or Th17 cells were activated with anti-CD3 antibody for 4h. DUSP11 expression 
was determined by QRT. * P < 0.01 (t-test). The data are a representative of three 
independent experiments. 
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2.2. Generation of Dusp11-/- mice 
 
To determine the function of DUSP11 in immune responses, mice deficient in 
DUSP11 were generated using an ES cell (BB0918) containing an insertion 
mutation, or gene trap, in the 1st intron of the DUSP11 gene.  The gene trap vector 
generates a spliced fusion transcript containing DUSP11, the β-geo cassette 
encoding β-Gal and the neomycin resistance gene (Fig. 5A). Genotypes of the 
embryos were determined by PCR using primers flanking the insertion in the wild-
type allele (P1 and P2, Fig. 5A) and the same forward primer (P1) plus a reverse 
primer in the vector (P3) (Fig. 5B). Further, western blotting analysis on bone 
marrow-derived dendritic cells (BMDCs) was used to confirm the disruption of the 
DUSP11 protein expression (Fig. 5C). Homozygous Dusp11-/- mice were fertile and 
indistinguishable in appearance from wild-type (WT) littermates. Further, the 
lymphoid immune cells developed normally in the absence of the DUSP11 gene (Fig 
6). Therefore, DUSP11 is dispensable for the development of the immune system.   
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Dusp11 -/- (gene trap) mouse generation. 
of WT and DUSP11 trapped alleles respectively. The gene trap vector containing 
galactosidase (β-geo) and neomycin transferase (neo) genes was inserted into the 
1st intron of the DUSP11  gene.(B)
tissues from Dusp11+/- x 
P1/P3 primer pairs shown in fig A
(C) DUSP11 deficiency in 
confirmed by western blotting.
experiments. 
(A) Schematic representation 
 Genomic DNA was isolated from embryonic 
Dusp11+/-  breeders for genotyping using P1/P2 and 
 to identify WT and mutated alleles, respectively. 
Dusp11-/- bone marrow derived dendritic cells was 
 The data are representative of three independent 
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Figure 6. Development of T, B, and dendritic cells is normal in Dusp11-/- mice. 
(A) Thymocytes and (B) splenocytes from WT and DUSP11 KO mice were stained 
with antibodies against TCR-β, CD4 and CD8 to analyze various T cell 
subpopulations. (C) Bone marrow cells are stained for B220 expressing IgM+ cells.  
(D) Splenocytes were stained with CD45R, CD11C and MHC-II antibodies and 
CD45R- populations were analyzed.  The data are representative of three 
independent experiments that yielded similar results. 
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2.3. Dusp11-/- mice are defective in immune responses against Listeria 
monocytogenes infection  
 
Innate and adaptive immunity plays principal protective roles in response to 
intracellular pathogen infection such as Listeria monocytogenes infection (Zenewicz 
and Shen, 2007). To study the role of DUSP11 in regulating pathogen-specific 
immune responses, we infected WT and DUSP11 knockout (KO) mice with 104 CFU 
of Listeria monocytogenes expressing ovalbumin (LM-Ova) on day 0. Serum IL-6 
and TNF-α were measured at different time points post infection (Fig 7A). DUSP11 
KO mice showed substantially reduced levels of pro-inflammatory cytokines 
compared to WT mice at 24h and 48h post infection. To examine if DUSP11 KO 
mice had any defect in bacterial clearance, on Day 3 or Day 7 post infection, livers 
were homogenized and plated to determine Listeria burden (Fig 7B).  We found that 
the bacterial burden in KO mice was significantly higher than in WT mice, indicating 
that DUSP11 KO mice are impaired in Listeria clearance.  
 
On day 3, splenocytes were isolated and the IFN-γ expressing cells were 
measured by intracellular staining after the surface staining of NK1.1 and TCR-β 
(Fig 8A). DUSP11 KO mice exhibited defective innate immune responses both in 
NK cells and NK T cells compared to the corresponding WT controls. Both CD4+ and 
CD8+ T cells are important in anti-Listeria immunity and bacterial clearance (Pamer, 
2004). To examine the regulation of anti-bacterial CD4+ and CD8+ T cell responses 
by DUSP11, 7 days post infection; splenocytes were stimulated with LLO peptide 
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and SIINFEKL peptides, respectively. Cells expressing IFN-γ, IL-17 or granzyme-B 
were measured by intracellular staining after surface staining with antibodies to CD4 
and CD8 (Fig 8B).  We found that both CD4+ and CD8+ T cell responses against 
Listeria antigens were highly compromised in DUSP11-deficient mice. Together, 
these results demonstrated that DUSP11 is essential for anti-Listeria immunity.   
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Figure 7. Dusp11-/- mice have defective proinflammatory cytokines secretion 
and defective bacterial clearance upon Listeria monocytogenes infection. (A) 
WT or Dusp11-/- mice were intravenously infected with 104 LM-Ova (n=5 per group). 
Serum TNF-α and IL-6 were measured by ELISA at different time points post 
infection. (B) On Day 3 or Day 7 post infection, livers were homogenized and plated 
to determine Listeria burden. * P < 0.05 (t-test). The data are representative of three 
independent experiments with similar results. 
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Figure 8. Dusp11-/- mice have defective innate and adaptive immune 
responses against Listeria monocytogenes infection in vivo.  (A) Three days 
post infection, splenocytes of the listeria infected mice were obtained, and the IFN-γ 
expressing cells were measured by intracellular staining after the surface staining of 
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NK1.1 and TCR-β. (B) Seven days post infection; splenocytes were stimulated with 
LLO peptide or SIINFEKL peptide overnight including 4 hour incubation with Golgi-
Stop and Golgi-Plug. Cells expressing IFN-γ, IL-17 or granzyme-B were measured 
by intracellular staining after the surface staining of CD4 and CD8. * P < 0.05 (t-test). 
Data shown are representative of three independent experiments.  
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2.4. Dusp11-/- mice have defective antigen specific immune responses in vivo 
 
To further confirm if Dusp11-/- mice are defective in antigen-specific T-cell 
responses, we employed a KLH immunization model. WT and DUSP11 KO mice 
were immunized with KLH in Complete Freunds Adjuvant (CFA). On day 7, 
splenocytes were isolated and were stimulated with varying concentrations of KLH 
protein. Cytokine production was determined by intracellular staining after overnight 
stimulation with KLH (Fig 9A) or by ELISA (Fig 9B) after 72h KLH stimulation. 
DUSP11 KO mice expressed decreased levels of both Th1 and Th17 cytokines (Fig 
9A and Fig 9B), suggesting that DUSP11 is required antigen-specific T cell 
responses in vivo. Further, to identify if humoral immune responses are 
compromised in Dusp11-/- mice, we also studied T follicular helper (Tfh) cells and 
germinal center B cell population in these mice.  We found reduced percentage of 
GL7+Fas+ germinal center B cells which is correlated with decreased CXCR5+Bcl6+ 
Tfh cells in the lymph nodes of Dusp11-/- mice compared to their WT counterparts 
(Fig 9C).    
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Figure 9. Dusp11-/- mice have defective KLH specific immune responses in 
vivo. (A) WT and Dusp11-/- mice were immunized with KLH in CFA. On day 7, 
splenocytes were isolated and stimulated with KLH peptide. Cytokine production 
was determined by intracellular staining after KLH re-stimulation. (B) 7 days post 
KLH immunization splenocytes were stimulated with different doses of KLH for 72h 
and IFN-γ and IL-17 were analyzed by ELISA. (C) Germinal center B cells were 
determined by staining with GL-7, FAS and B220 antibodies and Tfh cells by CD4, 
CXCR5 and BTLA antibodies. * P < 0.05 (t-test). Data shown are a representative of 
three independent experiments.    
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2.5. Dusp11-/- mice have defective innate immune responses in vivo and in 
vitro 
 
Considering that innate immune responses are compromised in Dusp11-/- 
mice in the early phase during Listeria infection (Fig 7 A&B), we directly studied 
their response to intraperitoneal injection of LPS. Following injection with 15 µg of 
LPS per g of body weight, WT and KO mice were monitored for signs of sepsis for 
48 h and serum IL-6 and TNF-α levels were measured at several time points. Similar 
to innate responses against Listeria, pro-inflammatory cytokine production in KO 
mice was attenuated post LPS injection (Fig 10A). Further, the KO mice were 
resistant to septic shock compared to their WT counterparts (Fig 10B). Together, 
these results highlight the importance of DUSP11 in innate immune responses in 
vivo.   
 
To investigate how DUSP11 regulates innate immune responses in vitro, DCs 
were generated from bone marrow cells of WT and DUSP11 KO and stimulated with 
various concentrations of LPS. IL-6 and TNF-α protein (Fig 11A) and mRNA (Fig 
11B) levels were measured. We found that upon LPS stimulation, the production of 
pro-inflammatory cytokines IL-6 and TNF-α was decreased in KO DCs compared to 
WT cells at both mRNA and protein levels (Fig 11). Further, we tested if 
macrophages have similar phenotype and identified that the bone derived 
macrophages from Dusp11-/- mice have phenotype similar to that of DCs but the 
defect is less compared to DCs.  
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Figure 10. Dusp11-/- mice have defective innate immune and inflammatory 
responses in vivo. (A) WT or Dusp11-/- mice were intraperitoneally injected with 
LPS. Serum TNF-α and IL-6 were measured by ELISA at different time points post 
infection. * P < 0.05 (t-test). (B) Post LPS injection, survival of the mice was 
monitored over the next 48 hours. Data are combined from two independent 
experiments and are from a total of 10 mice of each genotype. 
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Figure 11.  Dusp11-/- mice have defective proinflammatory cytokines secretion 
in vitro in dendritic cells upon stimulation with LPS. CD11c+ bone marrow 
derived dendritic cells from WT and Dusp11-/- were stimulated with different doses 
of LPS and mRNA and protein levels of IL-6 and TNF-α were measured using ELISA 
(A) and quantitative real-time PCR (B) respectively. * P < 0.05 (t-test).  Data shown 
are representative of three independent experiments.  
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Figure 12.  Dusp11-/- mice have defective proinflammatory cytokines secretion 
in vitro in macrophages upon stimulation with LPS. CD11b+ bone marrow 
derived dendritic cells from WT and Dusp11 -/- bone marrow macrophage cells were 
stimulated with different doses of LPS and mRNA levels of IL-6 and TNF-α were 
measured using quantitative real-time PCR. * P < 0.05 (t-test). Data shown are 
representative of three independent experiments. 
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2.6. DUSP11 is required for CD4 T cell activation and proliferation but 
dispensable for CD4 T cells differentiation in vitro  
 
To address the regulation of CD4+ T cell activation and proliferation by 
DUSP11, naïve CD4+ T cells from WT and DUSP11 KO mice were isolated and 
stimulated with plate-bound anti-CD3 antibody or anti-CD3 plus anti-CD28 
antibodies. IL-2 production in culture supernatants was determined by ELISA (Fig 
13A). We found that upon stimulation with anti-CD3 alone or anti-CD3 plus anti-
CD28 antibody, the production of IL-2, a hallmark of naïve T cell activation, was 
higher in DUSP11 KO CD4+ T cells than in WT cells. Furthermore, DUSP11 KO 
CD4+ T cells exhibited enhanced proliferation compared with WT cells in response to 
anti-CD3 antibody stimulation (Fig 13A). To examine the regulation of DUSP11 in T 
helper cell differentiation and effector function, WT and DUSP11 KO naïve CD4+ T 
cells were cultured under Th1, Th2 or Th17 differentiation conditions in vitro. After 4 
days of differentiation, effector Th cells were analyzed by intracellular cytokine 
staining. As shown in Fig 13B, Dusp11-/- Th1, Th2 and Th17 cells produced similar 
amounts of effector cytokines compared to WT cells. Together, these data 
demonstrate that DUSP11 is dispensable for Th1, Th2 and Th17 differentiation and 
function in vitro.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. DUSP11 is required for CD4 T cell activation and proliferation but 
dispensable for CD4 T cell differentiation
activated with different concentrations of anti
anti-CD28 and their IL-2 production and [3H]
Naïve CD4+ T cells from WT and 
and Th17 cells, followed by anti
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2.7. DUSP11 expression in dendritic cells is required to regulate the T helper 
cell responses in vitro and in vivo 
 
Though we did not observe any defect in Th differentiation by DUSP11 KO T 
cells in vitro (Fig 13B), we observed defective adaptive immune responses by 
DUSP11 KO mice in vivo (Fig 8B and Fig 9 A & B), which may possibly results from 
the defective innate immunity in these mice. To assess this idea, we employed a 
previously described DC-CD4 T cell co-culture system (Chung et al., 2009). CD4+ T 
cells from WT or KO mice were co-cultured with BM-derived DCs (WT or KO) in Th1 
or Th17 skewing conditions. IL-17- or IFN-γ−expressing T cells were measured by 
intracellular staining. We found that WT and KO T cells produced similar amounts 
IFN-γ or IL-17 when cultured with WT DCs, whereas KO DCs always exhibited 
reduced ability to induce cytokine expression by WT or KO T cells (Fig 14).  
 
To assess the in vivo relevance of these observations we performed an OT-II 
cells adoptive transfer experiment where Ly5.1+ positive OT-II CD4 T cells were 
adoptively transferred into Ly 5.2+ positive WT or KO recipient mice. Following the 
transfer, mice were immunized subcutaneously with OVA protein in CFA. Seven 
days post immunization; antigen specific responses produced by the transferred 
cells were analyzed by flow cytometry. We found that the transferred cells produce 
more IFN-γ in case of WT mice compared to the KO mice (Fig 15A).   
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To investigate whether CD4 T cells lacking DUSP11 have an intrinsic defect 
in vivo, we employed CD4 transfer EAE model (Zhang et al., 2009). We isolated 
CD4+ T cells from WT and DUSP11 KO mice and transferred 5×106 WT or KO cells 
into Rag1−/− mice, followed by immunization with MOG in CFA to induce EAE 
disease (Chung et al., 2009).  Rag1-/- mice that received WT and Dusp11-/- CD4 T 
cells developed disease around day 6 after second immunization and all the mice 
had disease scores between 2 and 3 by day 12 (Please refer to Chapter 5 to find the 
scoring scheme we followed). We did not observe any significant difference in 
disease kinetics between Rag1-/- group that received Dusp11-/- CD4 T cells 
compared to the group that received WT CD4 T cells demonstrating that DUSP11 
deficient T cells do not have intrinsic defect in EAE model (Fig 15B). Together, 
these results suggest a more important role of DUSP11 in innate immune cells, i.e. 
DCs, which ultimately regulates the adaptive T cell responses. 
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Figure 14. DUSP11 expression in dendritic cells modulates Th1 and Th17 
responses in vitro.  FACS-sorted naive CD4+ T cells from WT or KO mice were co-
cultured with BM-derived DCs (WT or KO) in the presence of soluble anti-CD3 Ab 
and LPS  to skew the cells towards  Th1 condition (A) or soluble anti-CD3 Ab and 
LPS  plus TGF-β to skew the cells towards  Th17  condition (B). IL-17- and IFN-γ 
expressing cells were measured by intracellular staining. Data shown are a 
representative of at least two independent experiments.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. DUSP11 expression
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and stained for Ly-5.1, Ly 5.2, CD4 and IFN-γ. IFN-γ producing adoptively 
transferred cells was analyzed.  Data shown are a representative of at least two 
independent experiments. (B) Naïve CD4+ T cells (5X106) from WT or Dusp11-/- 
mice were transferred into Rag1-/- recipient mice.  One day post transfer the 
recipient mice (5 mice per group) were immunized with MOG35–55 peptide to elicit 
EAE and disease was scored. Data shown are a representative of at least two 
independent experiments.   
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DISCUSSION 
 
 
DUSPs comprise a group of protein phosphatases that are characterized by 
their ability to dephosphorylate both phosphotyrosine and phosphoserine/Phospho-
threonine residues (Patterson et al., 2009).  DUSPs role as critical immune 
regulators is only being appreciated recently. Several recent studies by ours and 
several other groups highlighted the essentiality of these molecules in regulating 
innate and adaptive immune responses by modulating MAP kinase activities (Huang 
et al., 2011; Zhang et al., 2004; Zhang et al., 2009). We showed in this chapter that 
DUSP11 is critical for innate immune responses mediated by dendritic cells. 
 
DUSP11 was previously demonstrated to bind to ribonucleic acid-
ribonucleoprotein (RNA-RNP) complexes and RNA-splicing factors(Deshpande et 
al., 1999; Yuan et al., 1998) and is a p53 target gene (Caprara et al., 2009). Recent 
in vitro studies by Caprara et al (Caprara et al., 2009), Dardousis et al (Dardousis et 
al., 2007) and Hasler et al (Hasler et al., 2011) highlighted the possible function of 
this molecule in cell proliferation, cancer suppression and chronic inflammation. 
However, the physiological function of DUSP11 has not been studied via genetic 
approaches in vivo. In this study, we identified DUSP11 as an essential regulator of 
innate immune responses. Our findings demonstrate that although DUSP11 
expression is induced in vitro in both innate and adaptive immune cells upon 
stimulation by TLR ligands and TCR activation respectively, DUSP11 is dispensable 
for adaptive responses intrinsically in vitro and in vivo.  
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 Detailed analysis of innate and adaptive responses in vitro and in vivo by 
employing novel DUSP11-deficient mice that we generated highlighted the essential 
function of DUSP11 in proper innate responses, which eventually regulate the 
generation of adequate adaptive responses.  Our in vivo experiments using Listeria 
monocytogenes infection showed that Dusp11-/- mice had compromised serum 
proinflammatory cytokine levels and increased liver bacterial burdens on day 3 after 
infection (Fig 7 A and B). Correlating with these observations, we found that 
compared with WT mice, Dusp11-/- mice had defective pro-inflammatory cytokine 
production by DCs in response to LPS stimulation  in vitro (Fig 11) and were 
resistant to endotoxin induced septic shock in vivo (Fig 10). Further, studying the 
adaptive immune responses against L. monocytogenes infection on day 7 (Fig 8B) 
and using KLH immunization model (Fig 9) we demonstrated that antigen specific 
CD4+ T cell responses and B cell responses were compromised in the absence of 
DUSP11. 
 
Though we observed proliferation defect in Dusp11-/- CD4 T cells, we did not 
observe any defect in in vitro differentiation (Fig 13). This result suggested that 
DUSP11 is dispensable for adaptive immune responses. However, our in vivo KLH 
immunization (Fig 9) and Listeria infection (Fig 8) studies showed that the Dusp11-/- 
mice had compromised adaptive immune responses. To address this discrepancy 
between in vitro and in vivo data, using CD4 T cell-DC co-culture experiments we 
clearly demonstrated that DUSP11 is critical for innate immune responses and that 
the defects in innate responses ultimately affect the adaptive immune responses. In 
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conclusion, our findings establish DUSP11 as a critical regulator of innate immune 
responses which eventually impacts the induction of adaptive immune responses in 
vivo. To our knowledge, this is the first report to demonstrate the regulation of 
immune responses by DUSP11.  This is exciting to us because DUSP11 provides a 
potential target to treat inflammatory and infectious diseases. However, to pursue 
this avenue it is essential to understand the molecular mechanisms regulated by 
DUSP11 to affect the immune responses. In chapter 3 we attempted to understand 
this mechanism and identify the target molecule of DUSP11.  
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CHAPTER 3 – MOLECULAR MECHANISMS REGULTED BY DUSP11 IN 
DENDRITIC CELLS 
 
 
BACKGROUND 
 
 In Chapter 2 we demonstrated that DUSP11 is critical for proinflammatory 
secretion by dendritic cells. In case of adaptive immune CD4+ T cells we have 
identified that DUSP11 is dispensable for intrinsic regulation. In this chapter we 
attempted to understand the molecular mechanisms regulated by DUSP11 to 
mediate the proinflammatory cytokines secretion in dendritic cells upon stimulation 
by LPS, a TLR4 ligand. We hypothesized that DUSP11 regulates signaling pathways 
downstream of TLR receptor to mediate the proinflammatory cytokines secretion. 
The two main signaling pathways involved in proinflammatory cytokines secretion 
upon TLR stimulation are MAP Kinase and NF-κB signaling pathway (Newton and 
Dixit, 2012). So, we tested these two pathways in Dusp11-/- DCs in comparison to 
their WT counterparts upon LPS stimulation. Additionally, several studies to date 
have suggested that DUSP11 may function as RNA phosphatase. Therefore, we 
have tested whether DUSP11 effects the stability of proinflammatory cytokine-
encoding mRNA.  
 
 We have demonstrated that the decreased levels of pro-inflammatory 
cytokines produced by Dusp11-/- dendritic cells in response to TLR activation is 
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associated with reduced NF-κB activation in vitro. Furthermore, DUSP11 directly 
dephosphorylated the gamma binding domain (γbd) of IKK-β and thus positively 
regulated the activity of the IKK complex.  Together, we demonstrate for the first 
time that DUSP11 is a critical regulator of immune responses and acts specifically 
by mediating IKK activation during innate immune responses. This phosphatase thus 
could serve as a novel target for therapeutic intervention for inflammatory and 
autoimmune diseases.    
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RESULTS 
 
3.1 DUSP11 regulates MAP Kinase signaling in dendritic cells 
 
 To understand the molecular mechanisms regulated by DUSP11, we 
analyzed the MAP kinase signaling in WT and Dusp11-/- DCs following LPS 
stimulation by western blotting. Dusp11-/- DCs showed enhanced ERK and P38 
phosphorylation, but no difference in JNK phosphorylation in comparison to WT DCs 
(Fig 16A). To test if DUSP11 can directly regulate ERK and P38 activation, we 
overexpressed DUSP11 in 293 T cells by transfecting 293 T cells with increasing 
doses of DUSP11 plasmid with either MEK1 plasmid to activate ERK or MKK6 to 
activate P38. Only ERK but not P38 activity is decreased by DUSP11 in a dose-
dependent manner (Fig 16B). These data suggest that DUSP11 directly regulates 
ERK activity. To determine whether enhanced ERK activity is responsible for defect 
in proinflammatory cytokines secretion by Dusp11-/- DCs, we treated WT and 
Dusp11-/- DCs with ERK inhibitor and measured the proinflammatory cytokines 
secretion upon LPS stimulation by ELISA (Fig 17). ERK inhibitor treatment did not 
rescue proinflammatory cytokines defect in Dusp11-/- DCs suggesting that 
enhanced ERK activity is not responsible for the defect. 
 
 DUSP11 is previously suggested to function as mRNA phosphatase 
(Deshpande et al., 1999; Yuan et al., 1998). To test whether DUSP11 regulates 
stability of proinflammatory cytokine - encoding mRNA, we stimulated WT or 
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Dusp11-/- MEF cells with LPS followed by treatment with actinomycin-D (Fig 18). 
The half-lives of TNF-α and IL-6 mRNAs’ are similar between WT and Dusp11-/- 
MEF cells. These results demonstrate that DUSP11 does not regulate stability of 
proinflammatory cytokine- encoding mRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 16. DUSP11 regulates MAP Kinase 
or Dusp11-/- mice were stimulated with LPS
western blots were performed 
in 293 T cells by transfection in increasing dose of plasmid in presence of MEK1 to 
activate ERK or MKK6 to activate P38. 
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Figure 17. ERK inhibitor treatment cannot rescue defective 
cytokines secretion in Dusp11
cultured in presence or absence of ERK inhibitor (5 ng/ml) for 2h followed by 
stimulation with LPS (100 ng/ml) 
supernatants for the respective cytokines
least two independent experiments.
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Figure 18. DUSP11 does not regulate stability of proinflammatory cytokine- 
encoding mRNA.  Real-time PCR analysis of TNF-α (A) and IL-6 (B) mRNA in WT 
and Dusp11−/−  MEFs pretreated for 1 h with LPS (100 ng/ml), followed by 
treatment for 0–4 h (horizontal axes) with actinomycin D (5 µg/ml). Data shown are a 
representative of at least two independent experiments.  
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3.2 DUSP11 regulates NF-κB signaling in dendritic cells 
 
The increased ERK and p38 phosphorylation cannot possibly account for the 
defective pro-inflammatory cytokine production in Dusp11-/- DCs. We thus analyzed 
other signaling pathways involved in the production of pro-inflammatory cytokines. 
NF-κB signaling pathway is essential in the activation of pro-inflammatory cytokine 
production in addition to MAP kinase pathway (Ghosh and Hayden, 2012). So, we 
analyzed the NF-κB signaling pathway by studying the phosphorylation of IκB-α and 
found it was defective in the Dusp11-/- DCs compared to the WT controls (Fig 19A).  
An electrophoretic mobility shift assay (EMSA) using nuclear extracts from WT and 
Dusp11-/- DCs after stimulation with LPS further supported that the NF-κB binding 
was dramatically diminished in Dusp11-/- cells compared to WT cells (Fig 19B).  
Also, in vitro kinase assay using WT and KO DC lysates post LPS stimulation 
revealed that IKK function was defective in KO DCs (Fig 20A). Further, luciferase 
assay using WT and phosphatase inactive DUSP11 constructs demonstrated that 
DUSP11 directly regulates NF-κB activity in a phosphatase-dependent manner (Fig 
20B).  
 
 Also, RT-PCR analysis demonstrated that induction of several NF-κB target 
genes was defective in KO DCs compared to WT DCs (Fig 21). Together, our 
experiments indicate that DUSP11 deficiency impairs NF-κB signaling. Since ERK 
signaling was enhanced in Dusp11-/- cells, we tested if there is a crosstalk between 
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ERK and NF-κB pathways. We used an ERK inhibitor and found that inhibiting ERK 
signaling did not restore NF-κB activation in Dusp11-/- DCs (Fig 22). DUSP11 thus 
may have an unexpected direct effect on the NF-κB signaling pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 19.  DUSP11 regulates NF
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Figure 20. DUSP11 regulates NF
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plasmid, renilla luciferase plasmid and empty vector (empty) or vector encoding 
Flag-tagged DUSP11 (WT DUSP11) or vector encoding Flag-tagged phosphatase 
inactive DUSP11 (m-DUSP11), followed 20 h later by no stimulation (mock) or 
stimulation for 8 h with LPS (100 ng/ml) is measured; results are presented relative 
to the activity of renilla luciferase. Data shown are representative of at least two 
independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 21.  NF-κB target 
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Figure 22. ERK inhibitor treatment cannot rescue defective NF
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3.3 DUSP11 dephosphorylates the gamma binding domain (γbd) of IKK-β 
 
We further studied the upstream signaling components in NF-κB signaling 
pathway and found that TAK1 activation and IKK-α and IKK-β phosphorylation 
(Ser176/180 phosphorylation) was not defective in Dusp11-/- DCs upon LPS 
stimulation (Fig 23). However, our in vitro kinase assay showed that IKK activity is 
defective in the absence of DUSP11 (Fig 20A). Previous studies have demonstrated 
that IKK-α and IKK-β phosphorylation (Ser176/180 phosphorylation) is not sufficient 
for activation of IKK complex (Grabiner et al., 2007; Shambharkar et al., 2007). 
Several other modifications like ubiquitination and phosphorylation of other sites are 
also required (Grabiner et al., 2007; Higashimoto et al., 2008; Shambharkar et al., 
2007).  Of particular interests, the gamma binding domain (γBD) at the C-terminus of 
IKKβ has been shown to be phosphorylated, which negatively regulates IKK 
complex activity (Higashimoto et al., 2008). Polo like kinase 1 (PLK1) was described 
as the kinase that phosphorylates γBD (Higashimoto et al., 2008) but the 
phosphatase that dephosphorylates this domain has not yet been identified.  To 
examine if DUSP11 dephosphorylates γBD, we employed the HeLa cell line for in 
vitro studies as anti-p-γBD antibody is only available in human. Overexpression of 
WT but not phosphatase-inactive mutant of DUSP11 induced dephosphorylation of 
γBD (Fig 24A). Conversely, knocking down of DUSP11 expression using a DUSP11-
specific shRNA resulted in inhibition in LPS-induced de-phosphorylation of γBD (Fig 
24B). Using co-immunoprecipitation (Co-IP), we found that DUSP11 directly 
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interacted with IKK-β (Fig 24C), which was enhanced following LPS stimulation. 
Thus, DUSP11 appears to regulate the dephosphorylation of γBD. To test whether 
DUSP11 can directly de-phosphorylate γBD, an in vitro phosphatase assay was 
conducted using immunoprecipitated DUSP11 and IKK from 293T cells. Indeed, 
DUSP11 directly dephosphorylated γBD of IKK-β in vitro in a dose dependent 
manner (Fig 25A).  To verify if DUSP11 regulates the dephosphorylation of γBD in 
mice, we employed in vitro phosphatase assay where WT and KO DC lysates were 
incubated with IKK-β purified from HeLa cells and γBD phosphorylation was tested. 
As shown in Fig 25B, WT DC lysates dephosphorylated γBD more efficiently than 
KO DCs.   
 
To examine the γBD phosphorylation in WT and KO DCs directly, we 
generated mouse specific phosphoantibody against γBD (See under “Materials and 
Methods”). By performing western blots on DC lysates from WT and KO we 
confirmed the above results that γBD dephosphorylation is defective in the absence 
of DUSP11 (Fig 24D). Due to sensitivity issues of mouse phospho γBD antibody, 
these western blots were performed after immunoprecipitation of IKK complex using 
anti IKK-β antibody. It was previously proposed that γBD de-phosphorylation is 
essential for interaction of IKK-β and IKK-γ  (Higashimoto et al., 2008). We tested if 
DUSP11 KO DCs had any defect in this interaction by performing co-IP of IKK-β and 
IKK-γ but failed to find any difference between WT and KO DCs (Fig 26).  Together, 
we demonstrate that the γBD of IKK-β is a target of DUSP11 in innate immunity.  
  
 
 
 
 
 
 
 Figure 23. TAK1 and IKK
in Dusp11-/- dendritic cells.
measured in WT and DUSP11 KO DCs after stimulation with LPS (100 ng/ml)
shown are a representative of at least two independent experiments.
 
 
 
 
 
 
 
 
 
 
 
 
-α/β activation site phosphorylation is not defecti
 Phospho TAK1 and phospho IKK-
 
70 
ve 
α/β levels are 
. Data 
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and γBD phosphorylation was analyzed by western blotting stimulation with LPS 
(100 ng/ml).  (C) WT dendritic cell lysates were subjected to immunoprecipitation 
upon stimulation with LPS (100 ng/ml) with control immunoglobulin (Ig) or with 
antibody against IKK-γ.The immunoprecipitates were analyzed by western blotting 
with antibodies against DUSP11. IKK-β serves as a loading control. (D) Dendritic 
cells from WT or KO mice were stimulated with LPS (100 ng/ml) for the indicated 
times and IKK-β is immunoprecipitated from these cell lysates. Further, 
phosphorylation of γBD of IKK-β is analyzed in the immunoprecipitated samples 
using the mouse specific p-γBD antibody. Data shown are a representative of at 
least two independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 25. DUSP11 dephosphorylates 
Immunoprecipitated IKK complex from HeLa cells were incubated with increasing 
doses of immunoprecipitated DUSP11 and 
western blotting. IKK-β is used as loading control. (B) WT and DUSP11 KO DC 
lysates were incubated with immunoprecipitated IKK complex from HeLa cells and 
γBD phosphorylation was analyzed by western blotting
(100 ng/ml). Data shown are a representative of at least two independent 
experiments. 
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 Figure 26. IKK-β and IKK
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DISCUSSION  
 
In previously published in vitro studies, DUSP11 has been proposed to have 
a role in RNA metabolism (Deshpande et al., 1999; Yuan et al., 1998). However, 
these observations had not been confirmed in vivo. To understand the mechanisms 
by which DUSP11 regulates pro-inflammatory cytokine levels, we performed RNA 
stability experiments on IL-6 and TNF-α pro-inflammatory cytokine RNA from WT 
and Dusp11-/- DCs. However, we did not find any difference in the stability of these 
two RNAs (Fig 18), suggesting that DUSP11 may not regulate RNA metabolism in 
vivo.  Several other members of the DUSP family, such as DUSP1(Zhang et al., 
2009), DUSP10(Zhang et al., 2004), and DUSP16(Masuda et al., 2001), have been 
shown to specifically target the MAP kinase signaling pathway and dephosphorylate 
the MAP kinases ERK, JNK and P38.  We observed that, similar to other family 
members, DUSP11 also targeted MAP kinase signaling by dephosphorylating ERK 
and P38 (Fig 16A). Furthermore, we observed that DUSP11 positively regulates the 
NF-κB signaling pathway (Figs 19 & 20). These observations suggested that 
DUSP11 can be involved in cross talk between the MAP kinase and NF-κB signaling 
pathways. However, we found that inhibiting ERK signaling did not restore NF-κB 
activation in Dusp11-/- DCs (Fig 22). DUSP11 thus may have an unexpected direct 
effect on the NF-κB signaling pathway. Our in vitro kinase assay (Fig 20A) 
confirmed that NF-κB signaling is compromised at IKK complex in the absence of 
DUSP11. Further, our detailed mechanistic studies (Figs 24 & 25) confirmed that 
DUSP11 specifically targets and dephosphorylates the gamma binding domain of 
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IKK-β. Thus far, we have shown that DUSP11 specifically targets and 
dephosphorylates the gamma binding domain of IKK-β. It was previously proposed 
that γBD de-phosphorylation is essential for interaction of IKK-β and IKK-
γ (Higashimoto et al., 2008). We tested if Dusp11-/- DCs had any defect in this 
interaction by performing co-IP of IKK-β and IKK-γ but failed to find any difference 
between WT and KO DCs when the cells are activated (Fig 26). However, we 
identified that in the absence of DUSP11 the basal level phosphorylation of γBD is 
higher (Fig 24D) and accordingly the IKK-β and IKK-γ interaction is lower in the 
basal condition (Fig 26). These finding suggest us that in addition to 
dephosphorylating γBD, DUSP11 or its binding partners may additionally be required 
effective interaction of IKK-β with IKK-γ. So, the role of γBD of IKK-β in regulation of 
IKK activation and the requirement of DUSP11 in this process needs to be further 
studied.  
 
 In summary, although its deficiency enhances ERK and P38 activation in 
DCs, DUSP11 is unique among DUSPs in that it is the only known protein that 
positively regulates the activation of NF-κB pathway by serving as a phosphatase of 
the γBD of IKKβ. In resting cells the γBD remains phosphorylated by polo like kinase 
1 (PLK1) due to which the IKK complex remains inactive so that the signaling 
remains in the basal state. Upon stimulation with LPS, the γBD will be 
dephosphorylated by DUSP11 to activate the IKK complex there by activating the 
downstream signaling. How DUSP11 is activated upon TLR4 stimulation by LPS 
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needs further understanding (Fig 27). Considering this novel regulation by DUSP11 
is critical for the NF-κB activation in innate immunity, it may be considered as an 
attractive target to treat immune and septic diseases.   
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Figure 27. Proposed model for DUSP11 mediated regulation of NF-κB 
signaling. In resting cells the γBD remains phosphorylated by PLK1 due to which 
the IKK complex is inactive so that the signaling remains in the basal state. Upon 
stimulation with LPS, the γBD will be dephosphorylated by DUSP11 in addition to 
IKK-α and IKK-β phosphorylation at Ser 176/180 and Ser 177/181 respectively so 
that the IKK complex activity is enhanced there by activating the downstream 
signaling. How DUSP11 is activated upon TLR4 stimulation by LPS needs further 
understanding.  
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CHAPTER 4 – GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
DUSPs role as critical regulators of several physiological functions is 
discussed in Chapter 1. Herein we have focused on the role of DUSP11, an atypical 
DUSP, as regulator of immune responses and the molecular basis of this regulation. 
We analyzed the role of DUSP11 in innate and adaptive immune responses by 
generating the Dusp11-/- mice and studying them using several in vitro and in vivo 
experimental models.  We found that DUSP11 regulates proinflammatory cytokine 
secretion by dendritic cells by dephosphorylating a regulatory domain of IKK-β 
known as gamma binding domain (γBD). In Chapter 2, our findings demonstrate that 
although DUSP11 expression is induced in vitro in both innate and adaptive immune 
cells upon stimulation, DUSP11 is dispensable for adaptive responses in vitro.  
Further, our in vivo studies highlighted the requirement of DUSP11 in developing 
optimal innate responses, which regulates the generation of the adaptive responses 
in vivo. Together, we demonstrate for the first time that DUSP11 is a critical 
regulator of immune responses and acts specifically by modulating innate immune 
responses. This phosphatase thus could serve as a novel target for therapeutic 
intervention for innate cell-mediated inflammatory and autoimmune diseases.  
 
Additionally, in Chapter 3 we investigated the molecular mechanisms 
regulated by DUSP11 in immune responses. Since, we identified in Chapter 2 that 
DUSP11 is induced in dendritic cells upon TLR stimulation and that DUSP11 is 
critical in mediating innate immune responses, we focused our mechanistic studies 
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in dendritic cells upon TLR4 stimulation with LPS. Several other members of the 
DUSP family, such as DUSP1 (Zhang et al., 2009), DUSP10 (Zhang et al., 2004), 
and DUSP16 (Nallaparaju & Zhang et al. under review), were shown to specifically 
target the MAP kinase signaling pathways by dephosphorylating the MAP kinases 
ERK, JNK and P38.  We observed that, similar to other family members, DUSP11 
also targeted MAP kinase signaling by dephosphorylating ERK. Furthermore, we 
observed that DUSP11 positively regulates the NF-κB signaling pathway. These 
observations suggested to us that DUSP11 may be involved in cross talk between 
MAP kinase and NF-κB signaling pathways. IKK2 is the critical molecule of the NF-
κB signaling pathway shown to negatively regulate MAP kinase signaling (Waterfield 
et al., 2004). Our observations in Dusp11-/- mice with increased ERK activity and 
decreased NF-κB activity suggested that IKK2 could be a potential target of 
DUSP11. Of particular interest, the gamma binding domain (γBD) at the C-terminus 
of IKKβ has been shown to be phosphorylated, which negatively regulates IKK 
complex activity (Higashimoto et al., 2008). In this study Zandi and colleagues 
demonstrated that Polo like kinase 1 (PLK1) phosphorylates serines 733, 740, and 
750 of γBD in IKK-β during resting state and that this phosphorylation regulates the 
interaction of IKK-β with IKK-γ and thereby effects the IKK complex activity 
(Higashimoto et al., 2008). However, the phosphatase that dephosphorylates this 
domain has not yet been identified. Based on our phenotype in dendritic cells we 
hypothesized that DUSP11 is the phosphatase that dephosphorylates γBD. Our 
detailed mechanistic studies confirmed DUSP11 indeed regulates NF-κB activity by 
dephosphorylating the gamma-binding domain of IKK2. These mechanistic studies 
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highlight the role of DUSP11 as a positive regulator of NF-κB signaling, which 
ultimately affects the secretion of proinflammatory cytokines upon TLR stimulation in 
dendritic cells.  
 
In this chapter, we will relate our results to recent reports on DUSP11 and 
other family members’ role as regulators of immune responses and how this 
molecule can be targeted in future studies to treat inflammatory diseases and 
cancer. 
 
4.1. Role of DUSP11 in NF-κB signaling mediated proinflammatory cytokines 
secretion 
 
 DUSP members regulate immune responses mainly by regulating MAP 
Kinase signaling. Being a member of DUSP sub group we hypothesized that 
DUSP11 regulates MAP kinase activity by dephosphorylating one or more of their 
members. Though we identified that Dusp11-/- DCs have enhanced ERK and P38 
phosphorylation, this enhanced MAP kinase activity could not explain the defect in 
proinflammatory cytokines secretion by Dusp11-/- dendritic cells as enhanced MAP 
kinase signaling would result in enhanced cytokines secretion. MAP Kinase pathway 
and NF-κB signaling pathways are the two critical pathways involved in the secretion 
of proinflammatory cytokines (Newton and Dixit, 2012). To explain the 
proinflammatory cytokines secretion phenotype in Dusp11-/- DCs we analyzed the 
NF-κB signaling pathway and identified that NF-κB signaling is defective in the 
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absence of DUSP11 at the IKK complex level. We identified that upstream of IKK 
complex the NF-κB signaling pathway is intact in Dusp11-/- DCs. Further, we 
identified that IKK-α and IKK-β activation site phosphorylation (Ser176/180 
phosphorylation) is also comparable between WT and Dusp11-/- DCs. However, 
several recent studies have demonstrated that this phosphorylation by itself is not 
sufficient for activation of the IKK complex (Grabiner et al., 2007; Shambharkar et 
al., 2007). Several other modifications like ubiquitination and phosphorylation of 
other sites are also additionally required (Grabiner et al., 2007; Higashimoto et al., 
2008; Shambharkar et al., 2007). We went on to analyze additional phosphorylation 
sites of IKK-β due to its importance in regulating both NF-κB signaling and the ERK 
signaling and identified that DUSP11 regulates the activity of IKK complex by 
dephosphorylating γBD of IKK-β. Therefore, DUSP11 positively regulates the 
activation of the NF-κB pathway and promotes the secretion of proinflammatory 
cytokines.  
 
4.2. Role of DUSP11 in IKK complex activity 
 
 The transcription factor NF-κB is widely studied for its gene regulatory 
function as it activates large groups of genes in response to wide range of 
extracellular signals (May and Ghosh, 1999). Understanding the molecular 
mechanism that regulates NF-κB signaling is essential as this pathway is 
deregulated  in wide range of human diseases including cancer, autoimmune 
diseases and chronic inflammation (Sun and Liu, 2011).   In case of unstimulated 
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cells NF-κB is sequestered in the cytoplasm by inhibitory proteins IκBs. Upon 
stimulation by proinflammatory signals or other external stimuli like PAMPS, these 
IκBs are phosphorylated and degraded to release the NF-κB dimers so that they can 
translocate into nucleus and activate the transcription of their target genes. The 
upstream protein complex that phosphorylates the IκBs includes two catalytic 
subunits IKK-α and IKK-β and a regulatory subunit IKK-γ (also known as NEMO) 
(Ghosh et al., 1998). Together, this complex is known as IKK complex and the 
activity of this complex is tightly regulated by several modifications like 
phosphorylation at multiple sites and ubiquitination (Grabiner et al., 2007; 
Shambharkar et al., 2007). Previous studies have demonstrated that a domain in C-
termini of IKK-α and IKK-β known as Gamma binding domain (γBD) or nemo binding 
domain (NBD) is critical for their association with NEMO (May et al., 2000; May et 
al., 2002).  However, this domain of IKK-β but not that of IKK-α is essential for TNF-
α and IL-1β mediated NF-κB activation (Solt et al., 2009). This domain in IKK-β is 
previously demonstrated to be auto-phosphorylated by helix-loop-helix domain of 
IKK-β and is responsible for IKK-β activity (Delhase et al., 1999). Further, the same 
group has shown that mutating the serines in this domain to alanines resulted in 
higher basal activity as well as prolonged activation in response to the 
proinflammatory stimuli (Delhase et al., 1999). Another recent study by Zandi and 
colleagues demonstrated that PLK1 is the kinase that phosphorylates the γBD of 
IKK-β (Higashimoto et al., 2008).  But the phosphatase that dephosphorylates this 
domain has not yet been identified.   Our detailed mechanistic studies demonstrated 
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that DUSP11 directly dephosphorylates γBD of IKK-β to regulate IKK complex 
activity in canonical NF-κB pathway.  
 
 Further, Zandi and colleagues showed that phosphorylation of γBD regulates 
the interaction of IKK-β with IKK-γ and therefore plays a critical role for IKK activation 
(Higashimoto et al., 2008). We tested if Dusp11-/- DCs had any defect in this 
interaction by performing co-IP of IKK-β and IKK-γ but failed to find any difference 
between WT and KO DCs when the cells are activated. However, we identified that 
in the absence of DUSP11 the basal level phosphorylation of γBD is higher and 
accordingly the IKK-β and IKK-γ interaction is lower in the basal condition. These 
finding suggest us that in addition to dephosphorylating γBD, DUSP11 or its binding 
partners may additionally be required effective interaction of IKK-β with IKK-γ. So, 
the role of γBD of IKK-β in regulation of IKK activation and the requirement of 
DUSP11 in this process needs to be further studied. Cell permeable γBD peptide is a 
selective non- catalytic IKK inhibitor that disrupts the interaction of the catalytic 
subunits with NEMO, effectively blocking kinase activity that is triggered by many 
different inflammatory stimuli. This peptide is currently being evaluated in clinical 
studies with promising results for B-cell lymphoma and other forms of cancer 
(Habineza Ndikuyeze et al., 2014; Gamble et al., 2012) and inflammatory diseases 
(Edwards et al., 2009).  Since we demonstrated that DUSP11 directly regulates the 
activity of this domain, targeting DUSP11 may be a promising strategy in these 
diseases. 
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4.3. Role of DUSP11 in adaptive immune responses  
 
 Although DUSP11 expression is induced in vitro in both innate and adaptive 
immune cells upon activation, we have identified that DUSP11 is intrinsically 
dispensable for adaptive responses in vitro. Our results demonstrate that Dusp11-/- 
CD4 T cells have enhanced proliferation upon activation with anti-CD3 and anti-
CD28 antibody. This is in correlation with previous observations by Caprara et al that 
DUSP11 regulates cellular proliferation in a p53 dependent manner. However, when 
these CD4 T cells were differentiated into Th1, Th2 & Th17 subtypes in vitro.  There 
was no defect or enhancement when compared to their wild type counterparts. But 
in a L. monocytogenes infection model and KLH immunization model our studies 
demonstrated that Dusp11-/- mice have defective adaptive immune responses. To 
address this discrepancy between in vitro and in vivo data, we used in vitro co-
culture experiments and OT-II transfer experiments and demonstrated that DUSP11 
has an intrinsic defect in dendritic cells but in case of CD4 T cells DUSP11 is 
dispensable. However, the defect in innate immune cell production of 
proinflammatory cytokines eventually leads to defective adaptive immune responses 
in vivo.   These results support the growing body of evidence that intrinsic pathways 
in innate immune cells can modulate T cell lineage differentiation (Huang et al., 
2011).       
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4.4. DUSP11’s role as RNA phosphatase 
 
Several in vitro studies suggested that DUSP11 may function as an RNA – 5’ 
– phosphatase and has been proposed to have a role in RNA metabolism 
(Deshpande et al., 1999; Yuan et al., 1998). Further, these studies identified that 
DUSP 11 interacts with splicing factors like 9G8, SRp30C (Deshpande et al., 1999) 
and SAM68 (Caprara et al., 2009). However, these observations were not confirmed 
in vivo. To understand the mechanisms by which DUSP11 regulates 
proinflammatory cytokine levels, we performed RNA stability experiments on IL-6 
and TNF-α proinflammatory cytokine RNA from WT and Dusp11-/- DCs. However, 
we did not find any difference in the stability of these two RNAs, suggesting that 
DUSP11 may not regulate RNA metabolism of these cytokines in vivo. However, 
these studies are preliminary and further detailed mechanistic studies into RNA 
metabolism may provide better understanding into the role of DUSP11 as an RNA 
phosphatase.  
 
In case of C. elegans, a homologue of DUSP11 known as PIR-1 is shown to 
interact with Dicer DCR1 and was suggested to have a role in RNA silencing.   
Moreover, PIR-1 is essential for development, as the PIR-1 embryos fail to mature 
into adult worms (Duchaine et al., 2006). However, in the case of mice we have 
identified that DUSP11 is dispensable for development and the analyzed immune 
cell components are fully intact. So, although due the homological similarity of these 
proteins, it may be interesting to study the role of DUSP11 in RNA silencing, there 
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may be difference in function for DUSP11 in mammals as observed in the case of 
development.    
  
Bioinformatics analysis using Human Protein-Protein Interaction Mining Tool 
from Wei Li’s laboratory (He et al., 2009) helped us identify AUF-1 as a strong 
interacting partner of DUSP11 (Data not shown). AUF1, like DUSP11 is identified as 
an RNA binding protein and is suggested to have a role in RNA metabolism. A 
recent study identified AUF1 as a critical regulator of NF-κB signaling by maintaining 
proper levels of TAK1 an upstream kinase that phosphorylates IKK-β and activates 
NF-κB signaling  (Sarkar et al., 2011). These findings suggest that AUF1 interacts 
with DUSP11 and that these two proteins along with several other interacting 
partners may work as a complex that regulates   NF-κB signaling at different levels.  
 
4.5. DUSP inhibitors in preclinical metabolic, autoimmune diseases and cancer 
therapy trials   
 
Many members of DUSP family are overexpressed or hyper reactive in 
several human diseases including cancer and autoimmune diseases making them 
potential candidates for targeted therapy approach. The involvement of DUSPs in 
cancer and autoimmune diseases is well discussed in chapter-1. Here we will 
discuss the current status of their inhibitors in preclinical and clinical trials of 
autoimmune diseases and cancer. DUSP1 is a DUSP member whose role and 
molecular mechanisms are well documented in autoimmune diseases like 
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rheumatoid arthritis and in several varieties of cancer (Jeffrey et al., 2007; Rios et 
al., 2014; Wancket et al., 2012).  Depending on the type and the stage of disease its 
expression patterns and the regulatory mechanisms varies. Since this molecule is 
well studied in various disease models now it is being actively pursued as a 
therapeutic target (Pulido and Hooft van Huijsduijnen, 2008; Wancket et al., 2012). 
Targeted therapy against DUSP1 has been evaluated both at protein level and at 
mRNA level. In case of patients with major depressive disorder (MDD), DUSP1 
mRNA is overexpressed in the hippocampus resulting in diminished ERK activity. 
This condition is reverted by anti-depressant drug fluoxetine (Prozac). Additionally, 
DUSP1-/- mice were shown to be resistant to stress induced depressive like 
symptoms making the inhibition of DUSP1 a promising approach to treat depressive 
disorders (Duric et al., 2010). This approach is currently being considered for clinical 
trials in MDD patients (Rios et al., 2014).  
 
In cancer, DUSP1 expression patterns vary between tumor types and the 
stages of tumors and DUSP1 is shown to have both oncogenic and tumor 
suppressive functions depending on the type of cancer (Chan et al., 2008; Murty et 
al., 1996). These studies are discussed earlier in Chapter 1. It is essential to 
diagnose the stage of cancer and DUSP1 expression patterns in the patients before 
they are treated with DUSP1 inhibitors.  Several plant based derivatives like 
sangunarine and quinone derivatives or synthetic small molecular inhibitors like 
tricyclic pyrolle-2-carboxamide were shown to have inhibitory effects on DUSP1 in 
micro molar ranges (Nunes-Xavier et al., 2011). One such inhibitor, a plant based 
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triptolide-derivative Minnelide is currently evaluated in phase-II clinical trial in 
patients with advanced stage GI tumors where DUSP1 is overexpressed 
(ClinicalTrials.gov id: NCT01927965). Minnelide diminishes DUSP1 expression at 
the transcriptional level (Liu et al., 2011).   Further, in mouse models of spontaneous 
pancreatic cancer, Minnelide treatment is shown to promote survival of mice and is 
effective in reducing tumor growth (Chugh et al., 2012). In cancer types where 
DUSP1 functions as a tumor suppressive factor like in case of ovarian cancer (Murty 
et al., 1996)  or breast cancer, Bowman-birk inhibitor (BBI) could be used for therapy 
as this inhibitor significantly enhances DUSP1 expression upon addition to the cell 
lines (Chen et al., 2005).  
 
In case of atypical DUSP sub group members, DUSP3 inhibitors are currently 
being actively investigated in several disease models. Tertronic acid and 
phenylpyrazole derivatives have been demonstrated to have inhibitory effects on 
DUSP3 by inhibiting its enzyme activity (Nunes-Xavier et al., 2011). Currently these 
molecules are studied in disease models (Rios et al., 2014).  Some of the inhibitors 
like AS07234-4 are shown to have cross-inhibitory effects against both DUSP2 and 
DUSP 10 (Gobert et al., 2009).  Together, these studies highlight the potentiality of 
DUSP inhibitors as therapeutics against human diseases. Having identified the 
mechanisms by which DUSP11 regulates proinflammatory cytokines secretion by 
antigen presenting cells, DUSP11 targeting as a therapeutic strategy can now be 
tested in septic shock mouse models or patients or additionally in cancer mouse 
models or patients where NF-κB signaling is hyper activated (Staudt, 2010). 
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Recently, the high resolution structure of DUSP11 catalytic core has been reported. 
(Sankhala et al., 2014).  Now, small molecule inhibitors from natural sources and 
chemical libraries should be screened to identify molecules that can specifically 
inhibit DUSP11 activity or expression. Such inhibitors can have potential advantages 
over NF-κB inhibitors because unlike NF-κB inhibitors which block proinflammatory 
cytokines secretion completely, based on our KO data DUSP11 inhibitors only 
blocks them partially. As these cytokines have many immunological and 
physiological functions, partial blockade will be more advantageous than complete 
blockade. Thus, therapeutic inhibition of DUSP11 in cancers and septic shock 
patients deserves further exploration.  Moreover, DUSP11 is overexpressed in colon 
carcinoma and glioblastoma cell lines (Dardousis et al., 2007) suggesting a 
causative or biomarker role for DUSP11 in their pathology which can be further 
explored. 
 
4.6. Significance of the study and future directions 
 
 In summary we have identified DUSP11 as a critical regulator of immune 
responses against intracellular pathogens. In LPS induced septic shock mouse 
model that mimics human sepsis, we have shown that DUSP11 functions as positive 
regulator of proinflammatory cytokines secretion and the resultant multiple organ 
failure. Further, we have demonstrated that DUSP11 positively regulates 
proinflammatory cytokines secretion by innate immune cells. Mechanistically, we 
found that DUSP11 directly dephosphorylates the gamma binding domain (γbd) of 
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IKK-β and thus positively regulates the activity of the IKK complex. DUSP11 is 
unique that it is the only known DUSP member that positively regulates the 
activation of NF-κB pathway. Considering this novel regulation by DUSP11 is critical 
for the NF-κB activation in innate immunity, it serves as an attractive target to treat 
immune and septic diseases.  
 
 Although we have demonstrated that DUSP11 regulates NF-κB signaling by 
dephosphorylating γBD of IKK-β, the upstream signaling pathway that activates 
DUSP11 is not known. Further studies need to be carried out to identify the signaling 
pathway. Since NF-κB signaling is involved in regulation of several other signaling 
pathways like activation of inflammasome pathways or necrosis, the role of DUSP11 
as regulator of NF-κB in these pathways should be further studied. Also, we did not 
investigate the modifications required on DUSP11 like phosphorylation or 
ubiquitination to activate it. Further understanding the regulation of DUSP11 activity 
would provide a potential target molecule to moderately regulate NF-κB signaling 
pathway. Moreover, like discussed before, the role of DUSP11 as RNA phosphatase 
and its involvement in RNA silencing deserves further exploration. We also identified 
that Dusp11-/- DCs have enhanced ERK and p38 activation. Though our studies 
using the respective inhibitors have demonstrated that the enhanced MAP kinase 
activity is not responsible for defective proinflammatory cytokines secretion, this 
phenotype may be responsible for other physiological functions like cellular 
proliferation or cell cycle regulation.  The role of DUSP11 in these physiological 
processes needs to be further studied. Together, this study demonstrates that 
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DUSP11 is critical for innate immune responses and, as the first MAP kinase 
phosphatase that positively regulates NF-κB pathway; it may be targeted to treat 
immune diseases.  
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CHAPTER V – EXPERIMENTAL PROCEDURES 
 
Generation of Dusp11-/- mice: A targeted embryonic stem cell line with disruption 
of mouse DUSP11 by means of a gene-trapping vector inserted into intron 1 
(BB0918; Bay genomics) was injected into mouse blastocysts and subsequently 
transferred into pseudo pregnant foster mothers on a mixed C57BL/6:129 
background for the generation of chimeras, as described previously(Dong et al., 
1998). Heterozygous (+/-) mice were intercrossed to generate wild-type (WT) and 
mutant mice. To get the mice in B6 background we backcrossed the mixed 
background mice for six generations. All the experiments were performed first in 
mixed background mice and then were confirmed in B6 background mice with 
appropriate WT controls. OT-II mice with Ly5.1 congenic marker were generated by 
crossing OT-II mice with Ly5.1+ mice.  C57BL/6 and RAG1-deficient mice were 
purchased from Jackson laboratories. Mice were maintained in the animal care 
facility at The University of Texas MD Anderson Cancer Center, and the animal 
studies were approved by the Institutional Animal Care and Use Committee.  
 
In vitro DC and macrophage assays: Dendritic cells were cultured from bone 
marrow of WT and DUSP11 KO mice in presence of GM-CSF for 7 days as 
described previously(Chung et al., 2009). Macrophages were cultured from bone 
marrow of WT and DUSP11 KO mice in presence of M-CSF (L929 supernatant) for 
7 days as described previously (Zhong et al., 2013). CD11C+ or CD11B+ cells were 
sorted out from these cultured cells by staining with CD11C or CD11B magnetic 
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beads for DCs and macrophages respectively (Miltenyi Biotec). These cells were 
stimulated with varying concentrations of LPS for 4 h or 24h and proinflammatory 
cytokine levels were determined by real-time PCR and standard ELISA (BD 
Pharmingen, San Diego, CA) respectively.  
 
In vitro T cell assays: Naïve CD4+ T cells were purified from lymph nodes and 
spleens of mice by FACS based on the CD4+CD62LhiCD44lo and 
CD8+CD62LhiCD44lo surface phenotypes. To analyze the effects of DUSP11 on T 
cell activation and proliferation, T cells were incubated with different concentrations 
of plate-bound anti-CD3 antibody or anti-CD3 plus anti-CD28 antibodies. IL-2 
production by T cells was measured by ELISA (BD Pharmingen, San Diego, CA) 24 
h after T cell activation. Cell proliferation was determined at 72 h, after incubation 
with [3H] thymidine in the last 8 h. To examine the role of DUSP11 in effector 
function, naïve CD4+ T cells were cultured under Th1-, Th2-, or Th17-skewing 
conditions as described previously(Angkasekwinai et al., 2007). After 4 days of 
differentiation, cells were washed and treated with 2 µg/ml of plate-bound anti-CD3 
for cytokine measurement or treated with phorbol 12-myristate 13-acetate (PMA) 
and ionomycin in the presence of GolgiPlug (BD Biosciences) for intracellular 
cytokine staining, and samples were analyzed by flow cytometry. 
 
Real-time PCR analysis for mRNA expression: Total RNA was prepared from 
cells with TRIzol reagent (Invitrogen). Complementary DNA (cDNA) was synthesized 
with SuperScript reverse transcriptase and oligo(dT) primers (Invitrogen), and gene 
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expression was examined using a Bio-Rad iCycler iQ real-time PCR kit with iQ 
SYBR Green reagent. The data were normalized to the reference gene β-actin or 
GAPDH. The list of primers used in this study are shown in Table 1.  
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Table 2. List of Primers.  
 
 
 
 
 
 
 
 
 
 
 
a) Genotyping primers for genomic DNA (5’ to 3’) 
WT 
Forward 
 
GGCAGAAACCACATCCCCGAAAG 
WT 
Reverse 
 
TTACATCTATGAGCTGTCTC 
KO 
Forward 
 
GGCAGAAACCACATCCCCGAAAG 
KO 
Reverse 
 
TACAGTCCTCTTCACATCCATGCT 
b) Real time PCR primers 
 Gene 
name 
Primer sequence  forward  
(5’ to 3’) 
Primer sequence  reverse 
(5’ to 3’) 
DUSP11 GGCAGAAACCACATCCCCGAAA CTGGGAGATAGTCTTTCC 
IL-6 CACTTCACAAGTCGGAGGCTTA GCAAGTGCATCATCGTTGTTC 
TNF-α AATGGCCTCCCTCTCATCAGT GCTACAGGCTTGTCACTCGAATT 
iNOS CGAAACGCTTCACTTCCAA TGAGCCTATATTGCTGTGGCT 
MIP-1α CTGCCCTTGCTGTTCTTCTCTGT GGCTGCTGGTTTCAAAATAGTCA 
MIP-2 CCACTCTCAAGGGCGGTCAA CCCCTTATCCCCAGTCTCTTTCA 
GAPDH GAGAACTTTGGCATTGTGG ATGCAGGGATGATGTTCTG 
β-Actin TCCTTCGTTGCCGGTCCAC ACCAGCGCAGCGATATCGTC 
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mRNA stability experiments: Mouse embryonic fibroblasts (MEF) cells from WT or 
Dusp11-/- mice were stimulated for 1 h with LPS (100 ng/ml), followed by treatment 
(for mRNA decay) or no treatment (for steady state mRNA level) with 5 µM 
Actinomycin-D. Up to 4h hours post treatment, cells were harvested and mRNA was 
extracted as mentioned above (Zhong et al., 2012).  
 
KLH immunization: WT and DUSP11 KO mice were immunized were 
subcutaneously immunized at the base of tail (200 ul/ mouse) with keyhole limpet 
hemocyanin (KLH) protein emulsified in complete Freund’s adjuvant (CFA). Seven 
days post immunization the mice were sacrificed and analyzed individually for 
germinal center formation and antigen specific antibody and cytokine responses. 
Briefly, total spleen cells or LN cells (Tfh and GC B cell staining shown in figure are 
from LN cells) from these mice were stained for T follicular helper cells (Tfh) using 
PerCP labeled anti-CD4, biotinylated anti-CXCR5 mAb followed by APC labeled 
streptavidin and PElabelled anti-BCL6 mAbs (BD Biosciences). Germinal center B 
cells were detected by staining with FITC-labeled anti-GL7 and PE-labeled anti-Fas 
mAbs, and PerCP labeled anti-B220 mAb (BD Biosciences). To measure effector 
cytokine levels, ELISAs and intracellular staining techniques were used. On day 7, 
splenocytes or lymphocytes were isolated and stimulated with varying 
concentrations of KLH peptide. Cytokine production was determined by ELISA after 
3 days of stimulation or by intracellular staining after overnight stimulation.  For 
intracellular staining, cells were first stained with PerCPCy5.5-labeled anti-CD4 and 
then permeabilized with permeabilization buffer (BD Biosciences). They are further 
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stained with APC-labeled anti-IFN-γ and PE-labeled anti-IL17 (BD Biosciences). To 
measure KLH specific antibody responses, sera from immunized mice were 
collected and IgM, IgG, IgG1, and IgG2a antibodies were measured by ELISA. 
Briefly, plates were coated with 10 µg/ml of KLH protein followed by addition of sera 
from immunized mice in 3-fold serial dilution. Antigen specific antibodies are then 
detected using HRP conjugated anti mouse IgM, IgG, IgG1 and IgG2A antibodies 
(Southern Biotechnology Associates) respectively (Nurieva et al., 2008). 
 
Listeria monocytogenes infection: An erythromycin-resistant strain of Ova-
expressing Listeria monocytogenes (LM-Ova) was kindly provided by Dr. Michael 
Bevan (University of Washington). The bacteria were grown in brain-heart infusion 
media supplemented with 5 µg/ml erythromycin (Chung et al., 2013). The bacteria 
were harvested at mid-log growth phase and were intravenously (i.v.) injected into 
animals (1x104 colony forming units (CFU)/mouse). Three or 7 days after infection, 
the spleens and livers of the infected mice were harvested. The Listeria burden in 
the liver was determined by plating serial dilutions of liver cells, suspended in PBS 
with 0.1% NP40, on brain-heart infusion plates overnight. Splenocytes were 
stimulated with SIINFEKL peptide or LLO peptide overnight for intracellular cytokine 
staining or for 3 days for ELISA analysis (BD Pharmingen, San Diego, CA).   
 
Adoptive transfer and EAE induction: CD4+ T cells from spleens and LNs of WT 
and Dusp11-/- mice were purified by automacs sorting (Mitenyi Biotec, Auburn, CA) 
and 5X106 cells were adoptively transferred i.v. into Rag1-/- recipient mice. After 24h, 
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EAE was induced in these recipient mice by immunization with MOG35-55 peptide 
as described by our group previously (Dong et al., 2001). Briefly, mice were 
immunized with the peptide in CFA twice and two subsequent treatment of pertussis 
toxin, 1 day after each immunization. The mice were observed daily for clinical signs 
and scored on a scale of 0-5 with gradations of 0.5 for intermediate scores: 0, no 
clinical signs; 1, loss of tail tone; 2, wobbly gait; 3, hind limb paralysis; 4, hind- and 
forelimb paralysis; 5, death. Preparation and stimulation of mononuclear cells from 
brain and spinal tissues were done as described. 
 
DC/T cell co-culture experiments:  FACS-sorted naive CD4+ T cells from WT or 
KO mice were co-cultured with bone marrow-derived DCs (WT or KO) in the 
presence of soluble anti-CD3 antibody (0.2 mg/ml) and LPS or LPS (100 ng/ml) plus 
TGF-β (1 ng/ml). IL-17- or IFN-γ-expressing cells were measured by intracellular 
staining (Chung et al., 2009).  
 
Adoptive transfer experiments: FACS-sorted naïve CD4+ T cells (5X106) from 
spleens and lymph nodes of Ly-5.1+ OT-II mice were injected i.v. into congenic WT 
or KO recipient mice. One day later the recipient mice were subcutaneously 
immunized with OVA protein. Seven days post immunization the recipient mice were 
sacrificed and lymph nodes cells were stimulated overnight with OT-II peptide 
followed by intracellular staining (Soroosh et al., 2006).  
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Western blot analysis: For analysis of ERK, JNK, p38, and IκBα activation, WT 
and KO dendritic cells were activated with LPS for different times. In case of ERK 
and p38 inhibitor treatment experiments, ERK inhibitor (U0126 (Cell Signaling 
Technology, Beverly, MA)) or p38 inhibitor (SB203580 (Cell Signaling Technology, 
Beverly, MA)) is included in the cultures for 2 hrs before stimulation with LPS.  Cell 
lysates prepared as described previously(Zhang et al., 2009) were subjected to 
Western blot analysis with anti-phospho-ERK, anti-phospho-p38, anti-phospho-JNK, 
anti-phospho-IkBα, and anti-total IkBα antibodies (Cell Signaling Technology, 
Danvers, MA). Anti-total IKK-β and IKK-γ antibodies are purchased from Santacruz 
biotech. DUSP11 antibody is purchased from ProteinTech group.  Anti p-γBD 
antibody is obtained from Antagene Inc. The signal was detected with ECL reagent 
(Pierce Protein Biology Products). 
 
shRNA knock down: The short hairpin RNA (shRNA) lentiviral plasmid pLKO.1-
shDUSP11 (Oligo IDs: V3LHS_381810 & V3LHS_381808) or pLKO.1-shNS was 
purchased from MD Anderson shRNA and ORFeome Core. HEK 293T cells were 
co-transfected with the appropriate lentiviral plasmid together with the packaging 
vectors pRRE, VSV-G, and RSV-Rev to obtain lentiviruses. Packaged viruses were 
then used to infect HELA cells, which were treated with polybrene (8 mg/ml) and 
then selected in the presence of puromycin (1 mg/ml) for 7 days. The puromycin-
resistant cells were used for experiments. 
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EMSA: Nuclear extracts were prepared from WT and KO DCs after stimulation with 
LPS for indicated times and subjected to EMSA using the following 32P-radiolabelled 
oligonucleotide probes:NF- κB (5-CAACGGCAGGGGAATTCCCCTCTCCTT3) and 
NFY (5AAGAGATTAACCAATCACGTACGGTCT3) (Hu et al., 2013) 
 
Luciferase reporter assay: To identify if DUSP11 modulate NF-κB signaling, we 
constructed DUSP11 and phosphatase in active mutant DUSP11 expression 
plasmids and transfected those together with pGL3–NF-κB luciferase reporter (0.1 
µg) and a control pRL-TK renilla luciferase reporter (0.02 µg) into HeLa cells through 
the use of Lipofectamine 2000. 20 h after transfection, cells were stimulated with 
LPS for 8 h before luciferase assays (Zhong et al., 2012). 
 
Constructs: Mammalian expression plasmids for Flag- or Myc-tagged DUSP11 
were constructed in the pcDNA6.0 vector. Plasmids encoding phosphatase in active 
DUSP11 mutant was made with a site-directed mutagenesis kit (200519; 
Stratagene).  
 
LPS induced septic shock: Age- and sex-matched WT and DUSP11–/– mice were 
injected intraperitoneally with LPS (15 mg/kg). Survival was monitored every three 
hour for 48 hours. Blood was obtained at 3h and 6h after challenge, and the 
concentrations of TNF-α and IL-6, in the sera were measured by ELISA (Zhong et 
al., 2013).  
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In vitro kinase assay: Whole-cell lysates from WT and KO DCs were prepared in a 
kinase cell lysis buffer supplemented with phosphatase inhibitors after stimulation 
with LPS for indicated times and subjected to coimmunoprecipitation using IKK-
γ antibody. The immunoprecipitates are then subjected to in vitro kinase assays as 
described previously (Zhang et al., 2008). 
 
In vitro phosphatase assay: In vitro phosphatase assay was performed using 
immunoprecipitated DUSP11 from 293T cells overexpressing DUSP11 and 
immunoprecipitated IKK complex from HELA cells. IKK complex was incubated with 
increasing doses of DUSP11 in phosphatase assay buffer(Lorenz, 2011)  and 
phosphorylation of γBD of IKK-β was analyzed by western blotting. To test if 
DUSP11from dendritic cells can dephosphorylate γBD, DC lysates from WT and KO 
were incubated with immunoprecipitated IKK complex from HELA cells and 
phosphorylation of γBD of IKK-β was analyzed by western blotting.  
 
Co-immunoprecipitation: Co-IPs were performed as described previously(Zhong et 
al., 2013). Briefly, standard immunoprecipitations were performed under normal 
conditions in lysis buffer [20 mM tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-
40], and the immunoprecipitates were subjected to standard Western blotting 
analysis.   
 
Generation of mouse specific phosphoantibody against γ-binding domain: 
Mouse specific phosphoantibody against γ-binding domain was generated in rabbits 
 103 
against phosphorylated FTTLDW(pS)WLQME peptide using outside vendor (Pierce 
Biotechnology, Inc.). Phosphoantibodies are enriched in the serum by affinity 
purification process; first by passing through non-phospho-peptide column to remove 
non phospho antibodies followed by phospho-peptide column.   
 
Antibodies used for flow cytometric analysis:  The following antibodies were 
used for cell surface and intracellular staining: PerCP/Cy5.5 or FITC-labeled anti-
TCR-β(clone H57-597), PerCPCy5-5-labeled anti-CD4 (clone GK1.5), Alexa 488-
labeled anti-CD8 (clone 5H10-1), and APC-labeled anti-CD11b (clone M1/70), all 
from Bio legend; and PE- or Alexa 488-labeled anti-IFN-γ (clone XMG1.2), PE-
labeled anti-IL-17 (clone TC11-18H10), Alexa 647-labeled anti-granzyme B (clone 
GB11), FITC- or PerCPCy5.5-labeled anti-NK1.1 (clone PK136), and PerCPCy5-5-
labeled anti-Ly6C (clone AL21), all from BD Biosciences. For intracellular staining, 
cells were permeabilized with permeabilization buffer (BD Biosciences) and then 
further stained with the intracellular staining antibodies described above. These cells 
were analyzed by using an LSRII flow cytometer (BD Biosciences) and FlowJo 
software (Tree Star, Inc.).  
 
Statistical analysis: The Student t test was used to assess the statistical values. P 
values were determined, along with standard error of the mean (SEM) or standard 
deviation (SD) using STATISTICA software (StatSoft, Inc., Tulsa, OK). P values < 
0.05 were considered significant.  
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